Faculty Appointments
Research Associate Professor of Biochemistry
Research Associate Professor of Biomedical Engineering
Education
Ph.D., Organic Chemistry, Shinshu University, Nagano, JapanM.S., Chemistry, University of Dhaka, Dhaka, BangladeshB.S., Chemistry, University of Dhaka, Dhaka, Bangladesh
Office Address
Department of Biochemistry, Vanderbilt University School of Medicine
23rd at pearce
nashville, TN 37232-0146
23rd at pearce
nashville, TN 37232-0146
Research Description
FACULTY APPOINTMENTS AT VANDERBILT UNIVERSITY:
Research Associate Professor, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville TN 37232 USA
Research Associate Professor, Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville TN 37240 USA
NATIONAL AWARDS:
1. National Institutes of Health (NIH), National Research Award, R01 CA260958-01A1 (Role: Principal Investigator/Program Director) 7/05/2021–06/30/2026, $3M.
2. Phi Beta Psi National Research Awards, AWD00001248 and AWD00000652 (Role: Principal Investigator/Program Director) 08/01/2022-08/15/2024, $140K.
RESEARCH INTERESTS:
Jashim's research interests include development of targeted imaging agents for early detection of cancer and discovery of a gene therapy for effective treatment of neoplastic diseases. These projects have been funded by the Phi Beta Psi (PBP) Trust and the National Institutes of Health (NIH) of the United States of America.
MAJOR ACCOMPLISHMENTS:
1. Fluorocoxib A and Its Nanoparticles.
Fluorocoxib A, discovered by Md. Jashim Uddin and colleagues at the Vanderbilt University School of Medicine, is a fluorescent COX-2–selective inhibitor that enables targeted optical imaging of inflammation and cancer in vivo by binding sites of COX-2 overexpression, which is common across inflamed tissues and many solid tumors. It was subsequently formulated for improved delivery, validated across multiple disease models, licensed for commercialization as the XenoLight RediJect COX-2 Probe (Fluorocoxibs), and its platform is highlighted in the Springer medical volume “Imaging Inflammation” (ISBN 978-3-031-23660-0; ISSN 1422-7746).
Scientific discovery: Uddin’s team created Fluorocoxib A (FA) by conjugating a COX-2–inhibitory scaffold with 5-carboxy-X-rhodamine to yield a fluorescent small-molecule that selectively accumulates where COX-2 is induced, enabling noninvasive detection of inflamed and neoplastic tissues in vivo.¿ Follow-on studies from Uddin and collaborators showed FA retains selective COX-2 inhibition at submicromolar concentrations and produces strong lesion-to-background contrast in disease models, including retinal laser–induced choroidal neovascularization and tumor xenografts, with blocking by celecoxib confirming on-target binding.
Nanoparticle formulations: Nanoparticles of fluorocoxib A (FA-NPs) are developed with Vanderbilt bioengineers solubilized poorly water-soluble FA, enabling intravenous dosing, optimal imaging windows at 4–8 h post-injection, and 10-fold higher fluorescence in inflamed or tumor tissue versus normal tissue, supporting translational potential.
Significance for imaging: Because COX-2 is broadly upregulated in inflamed lesions and most solid tumors, FA provides a molecular readout of pathological prostaglandin biology that can aid early detection, staging, and treatment monitoring across oncology and inflammatory diseases.¿ In vivo FA imaging demonstrated high specificity and strong signal-to-background in multiple models (e.g., head and neck tumor xenografts, retinal inflammation), establishing COX-2 as a practical optical target for lesion localization and margin visualization. The FA platform catalyzed development of additional COX-2 probes (e.g., CF3-FA, near-infrared derivatives), expanding applications to endoscopy and image-guided procedures in preclinical and veterinary translational settings.
Licensing and commercialization: The COX-2 fluorescent probe technology from Vanderbilt University (Marnett Lab) has been licensed to Caliper Life Sciences and launched commercially as the XenoLight RediJect COX-2 Probe (Fluorocoxibs) for preclinical imaging on IVIS/Maestro platforms, marking the first market deployment of FA-based COX-2 optical probes. Launch communications emphasized licensing from Vanderbilt and positioned the probe for noninvasive COX-2 detection in oncology and inflammation research, enabling biomarker-guided studies and therapeutic response assessment in live animal models. Caliper’s imaging reagent portfolio (later acquired by PerkinElmer/Revvity) integrated the COX-2 probe with widely used optical systems, fostering broad adoption in preclinical research workflows.
Textbook inclusion of XenoLight: The XenoLight COX-2 probe platform is featured in the medical textbook “Imaging Inflammation” from Springer Nature Switzerland AG (ISBN 978-3-031-23660-0; ISSN 1422-7746), reflecting its recognition as a state-of-the-art molecular imaging approach for inflammatory biology. Vanderbilt’s profile for Uddin explicitly notes the inclusion of the XenoLight probe in the textbook “Imaging Inflammation,” with the Springer DOI listed, linking FA’s translational trajectory from discovery to educational canon in inflammation imaging.
2. Fluorocoxib Q and Its Nanoparticles.
Fluorocoxib Q (FQ) is a groundbreaking molecular probe discovered and developed for the highly specific imaging of cyclooxygenase-2 (COX-2) activity in living cells and animals. The discovery was led by Md Jashim Uddin at Vanderbilt University School of Medicine as an advancement over previous COX-2 imaging agents.
Discovery of Fluorocoxib Q: FQ is the first redox-activatable optical probe specifically designed to target COX-2, an enzyme overexpressed in many inflammatory, premalignant, and malignant tissues. The molecule consists of a nonsteroidal anti-inflammatory drug conjugated to a carboxy-X-rhodamine fluorophore, with a quenching nitroxide group (4-amino-TEMPO) attached. In its default state, FQ has very low fluorescence, making it almost undetectable in normal tissues. Upon entering pathologic tissues, reactive oxygen species (ROS) present in the disease environment reduce FQ to its fluorescent form (FQ-H), which then binds to COX-2, enabling high-contrast, real-time imaging.
Significance of Fluorocoxib Q: Enhanced specificity, FQ activates fluorescence only in redox-rich (ROS-abundant) environments, ensuring signal turns on selectively in diseased tissues with high COX-2 and ROS, minimizing background noise and false positives.
Real-Time In Vivo Imaging: This probe has enabled unprecedented visualization of COX-2 in live animal models, making it a valuable tool for studying inflammation, early cancer progression, and response to therapeutics.
Theranostic Potential: The ability to differentiate between pathologic and normal tissues in real time opens new avenues for targeted diagnosis and image-guided therapy of cancer and inflammatory diseases.
Translational Value: Because of its high metabolic stability and long circulation half-life, FQ accumulates at disease sites, potentially improving both preclinical research and future clinical diagnostics in oncology.
The discovery of Fluorocoxib Q represents a major leap in molecular imaging by allowing highly specific, background-free imaging of COX-2-driven disease processes in living organisms, aiding both research and the development of targeted therapies.
3. Chemocoxib A and Theranostics
Md Jashim Uddin's discovery of Chemocoxib A (CA) represents a breakthrough in the development of theranostic agents for breast cancer, as it is the first validated cytotoxic cyclooxygenase-2 (COX-2) inhibitor used for targeted imaging and treatment of tumors.
Discovery of Chemocoxib A: Chemocoxib A was discovered discovered by Md Jashim Uddin at the Vanderbilt University School of Medicine through a conjugate chemistry approach combining indomethacin (a COX inhibitor) and podophyllotoxin (a potent cytotoxic agent), resulting in a molecule with both high COX-2 selectivity and cytotoxicity. X-ray crystallography confirmed its tight binding to COX-2, and biochemical assays demonstrated that CA selectively inhibits COX-2 and accumulates in COX-2–positive tumor cells, without affecting normal cells lacking COX-2 expression.
Mechanism and Theranostic Platform: Uddin synthesized Chemocoxib A together with the imaging agent fluorocoxib Q (FQ), co-encapsulating both in reactive oxygen species (ROS)-responsive polymeric micellar nanoparticles (FQ-CA-NPs). These nanoparticles enable, a) COX-2-targeted delivery and retention within breast tumors, b) ROS-triggered release of cargo (FQ and CA) in the tumor microenvironmen, c) Fluorescence activation for real-time, image-guided confirmation of drug delivery, d) When administered intravenously in mouse models, FQ-CA-NPs selectively released their therapeutic and imaging cargos within COX-2–expressing breast cancer tissue, allowing direct visualization and significant tumor growth inhibition without systemic toxicity or damage to healthy tissue.
Clinical and Scientific Significance: The discovery of Chemocoxib A is significant milestone because it is the first cytotoxic COX-2 inhibitor validated for in vivo targeted therapy. Its cancer cell–selective cytotoxicity spares normal, COX-2–negative tissues, minimizing side effects. The theranostic platform allows clinicians to both image and treat breast tumors with a single formulation, providing real-time feedback on drug delivery success with high molecular specificity and enabling image-guided optimization of therapeutic regimens. Md Jashim Uddin's Chemocoxib A advances breast cancer theranostics by integrating selective, image-guided therapy and diagnostic capabilities, addressing challenges in both drug targeting and treatment verification.
PATENTS:
2025
Anti-COX-2 nanobodies for endoscopic visualization of colorectal adenomas (US 20250242062 A1, 2025). Disclosed subject matter comprised of methods and composition of nanobodies and their fluorescent conjugates for optical imaging of adenomas of the colon.
Compositions and methods for reducing AKR1C3 in castration-resistant prostate cancer and polycystic ovary syndrome (VU25034P1, 093386-0076-US01). Disclosed subject matter comprised of ligands of E3 ligases conjugated to indomethacin to proteolytically degrade AKR1C3 for the treatment of castration-resistant prostate cancer and polycystic ovary syndrome.
Indomethacin-based degraders of AKR1C3 in castration-resistant prostate cancer (VU41258780 2025). Disclosed subject matter comprised of indomethacin anchored ligands of E3 ligases for the treatment of prostate cancer.
Naproxen-based degraders of AKR1C3 in Prostate Cancer (VU51620495 2025). Disclosed subject matter comprised of naproxen anchored E3 ligase ligands for the treatment of prostate cancer.
2020
Compounds and methods for imaging cancer (US0280543 A1 2018, US 10,792,377 B2 2020). Disclosed materials are diagnostic agents comprised of a radical and a fluorophore moiety. Disclosed technology methods for developing smart probes enable visualization of cells associated with cancer, inflammation, or disorders associated with carcinogenesis.
Composition and method for detecting hypoxia (US 179117 A1 2016, US10,695,446 B2 2020). Disclosed subject matter comprised diagnostic agent conjugated to a hypoxia marker moiety. Disclosed methods and compositions for diagnosing (i.e., by optical imaging) hypoxic cells and/or treating a disorder associated with hypoxia.
2017
Fluorocoxib A loading into ROS-responsive nanoparticles (US0007723 A1 2017, US 10,105,455 B2 2018). Disclosed are compositions and methods for making and using the disclosed compositions. In a further aspect, disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle.
2010
Methods and compositions for diagnostic and therapeutic targeting of COX-2 (US 0254910 A1 2010, WO149456 A2 2007, WO149456 A3 2007, US 8,865,130 B2 2014). Disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also, provided are methods for using the disclosed compositions for diagnosing (i.e. by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activities.
PUBLICATIONS:
2025
Uddin MJ. Advances in Imaging Retinal Inflammation. Experimental Eye Research. 2025, 259, 110537.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman, A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F. Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Micellar Nanoparticles Enables Targeted Visualization of Drug Delivery in Breast Cancer. Molecular Pharmaceutics. 2025, 22, 2392-2401.
Asaduzzaman A, Thompson, CC, Sibai F, Uddin MJ, Application of Ensemble Learning Models in Computer-Aided Diagnosis of Skin Diseases. Neural Computing and Applications. 2025, 37:16735–16751.
Asaduzzaman A, Thompson, C, Sibai F, Uddin MJ, Using The Cancer Genome Atlas from cBioPortal to Develop Genomic Datasets for Machine Learning Assisted Cancer Treatment. BIORXIV/2025/638660
Lobban R, Carroll M, Vest V, Josh T, McCune JTM, Hall S, Yu F, Uddin MJ, Marnett LJ, Duvall CL, Leon M. Bellan LM. COOLING-TRIGGERED RELEASE OF CELECOXIB FROM IMPLANTABLE ALGINATE-SOLUPLUS COMPOSITE DEVICES. ACS Biomaterials Science and Engineering. 2025, 11, 5413-5425.
2024
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin, MT, Nazmin, F, Rahman, MS, Jashim A, Crews, BC, Kingsley, PJ, Marnett, LJ, Duvall, CL, Cook, RS. Polymeric Micellar Nanoparticles Enable Image-guided Drug Delivery in Solid Tumors. BioRxiv. 2024 Jun 6/7/2024; DOI: 10.1101/2024.06.07.598019.
Lo JH, Gbur EF, Francini N, Ma J, Sorets AG, Fletcher RB, Yu F, D'Arcy R, Oltman CG, Uddin MJ, Duvall CL. Synthesis and characterization of chloroquine-modified albumin-binding siRNA-lipid conjugates for improved intracellular delivery and gene silencing in cancer cells. bioRxiv. 2024 Oct 17;. doi: 10.1101/2024.10.14.618042. PubMed PMID: 39464033; PubMed Central PMCID: PMC11507671.
Asaduzzaman A, Thompson CC, Uddin MJ. Improving CADx System Performance for Skin Disease Detection using Ensemble Machine Learning
Models. IEEE TechRxiv, May 02, 2024. DOI: 10.36227/techrxiv.171467652.28972099/v1
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. BioRxiv. 2024 May 5/12/2024; DOI: 10.1101/2024.05.12.593773.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/8/2024; DOI: 10.1021/acsomega.4c03640.
2023
Uddin MJ, Niitsu H, Coffey RJ, Marnett LJ. Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas [letter]. J Biomed Opt [print-electronic]. 2023 Apr; 28(4): 40501. PMID: 37091910, PMCID: PMC10118138, PII: 220308LR, DOI: 10.1117/1.JBO.28.4.040501, ISSN: 1560-2281.
Aleem AM, Kang W, Lin S, Milad M, Kingsley PJ, Crews BC, Uddin MJ, Rouzer CA, Marnett LJ. Ferroptosis Inhibitors Suppress Prostaglandin Synthesis in Lipopolysaccharide-Stimulated Macrophages. ACS Chem Biol [print-electronic]. 2023 Jan 1/13/2023; PMID: 36638351, DOI: 10.1021/acschembio.2c00869, ISSN: 1554-8937.
2022
Uddin MJ, Lo JH, Oltman CG, Crews BC, Huda T, Liu J, Kingsley PJ, Lin S, Milad M, Aleem AM, Asaduzzaman A, McIntyre JO, Duvall CL, Marnett LJ. Discovery of a Redox-Activatable Chemical Probe for Detection of Cyclooxygenase-2 in Cells and Animals. ACS Chem Biol [print-electronic]. 2022 Jul 7/15/2022; 17(7): 1714-22. PMID: 35786843, DOI: 10.1021/acschembio.1c00961, ISSN: 1554-8937.
2021
Winters ND, Bedse G, Astafyev AA, Patrick TA, Altemus M, Morgan AJ, Mukerjee S, Johnson KD, Mahajan VR, Uddin MJ, Kingsley PJ, Centanni SW, Siciliano CA, Samuels DC, Marnett LJ, Winder DG, Patel S. Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. J Clin Invest [print-electronic]. 2021 Jul 7/22/2021; 131(17): PMID: 34292886, PMCID: PMC8409586, PII: e146861, DOI: 10.1172/JCI146861, ISSN: 1558-8238.
2020
Malerba P, Crews BC, Ghebreselasie K, Daniel CK, Jashim E, Aleem AM, Salam RA, Marnett LJ, Uddin MJ. Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1837-42. PMID: 33062161, PMCID: PMC7549111, DOI: 10.1021/acsmedchemlett.9b00280, ISSN: 1948-5875.
Uddin MJ, Xu S, Crews BC, Aleem AM, Ghebreselasie K, Banerjee S, Marnett LJ. Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1881-5. PMID: 33062168, PMCID: PMC7549255, DOI: 10.1021/acsmedchemlett.9b00555, ISSN: 1948-5875.
Uddin MJ, Vemulapalli A, Niitsu H, Crews BC, Oltman CG, Kingsley PJ, Kavanaugh TE, Bedingfield SK, Mcintyre JO, Milad M, Aleem AM, Coffey RJ, Duvall CL, Marnett LJ. Molecular Imaging of Inflammation in Osteoarthritis Using a Water-Soluble Fluorocoxib. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1875-80. PMID: 33062167, PMCID: PMC7549260, DOI: 10.1021/acsmedchemlett.9b00512, ISSN: 1948-5875.
Cekanova M, Pandey S, Olin S, Ryan P, Stokes JE, Hecht S, Martin-Jimenez T, Uddin MJ, Marnett LJ. Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. J Biomed Opt. 2020 Aug; 25(8): PMID: 32860356, PMCID: PMC7456637, PII: JBO-200044R, DOI: 10.1117/1.JBO.25.8.086005, ISSN: 1560-2281.
2019
Bourn J, Rathore K, Donnell R, White W, Uddin MJ, Marnett L, Cekanova M. Detection of carcinogen-induced bladder cancer by fluorocoxib A. BMC Cancer. 2019 Nov 11/27/2019; 19(1): 1152. PMID: 31775672, PMCID: PMC6882158, PII: 10.1186/s12885-019-6366-x, DOI: 10.1186/s12885-019-6366-x, ISSN: 1471-2407.
Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega [print-electronic]. 2019 May 5/31/2019; 4(5): 9251-61. PMID: 31172046, PMCID: PMC6545551, DOI: 10.1021/acsomega.9b01093, ISSN: 2470-1343.
Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ. Conjugated Indomethacin Fluorescent Inhibitors Utilize the Membrane Binding Domain of Cyclooxygenase-2 to Accommodate the Tethered Moiety. J. Biol. Chem. 2019 Apr 4/30/2019; 294(22): 8690-8. PMID: 31000626.
Bourn J, Pandey S, Uddin MJ, Marnett LJ, Cekanova M. Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. Oncotarget. 2019 Jan 1/29/2019; 10(48).
2018
Shaheen SM, Azad AK, Rahman MM, Uddin MJ. A comparative transgene expression study between a protaplex and a rotaplex embedded lipid-nanoparticles in murine derived dendritic cell. J Interdiscipl Nanomed. 2018 Jul 7/10/2018; 0(0).
Cavener VS, Gaulden A, Pennipede D, Jagasia P, Uddin J, Marnett LJ, Patel S. Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Front Neurosci. 2018; 12: 479. PMID: 30108473, PMCID: PMC6080414, DOI: 10.3389/fnins.2018.00479, ISSN: 1662-4548.
2017
Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, Uddin MJ, Plath N, Marnett LJ, Patel S. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biol. Psychiatry [print-electronic]. 2017 Oct 10/1/2017; 82(7): 488-99. PMID: 28438413, PMCID: PMC5585044, PII: S0006-3223(17)31357-4, DOI: 10.1016/j.biopsych.2017.03.002, ISSN: 1873-2402.
Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nat Commun. 2017 Mar 3/28/2017; 8: 14782. PMID: 28348378, PMCID: PMC5379055, PII: ncomms14782, DOI: 10.1038/ncomms14782, ISSN: 2041-1723.
2016
Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron [print-electronic]. 2016 Sep 9/21/2016; 91(6): 1244-52. PMID: 27618677, PII: S0896-6273(16)30509-8, DOI: 10.1016/j.neuron.2016.08.017, ISSN: 1097-4199.
Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ. Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. ACS Chem. Biol [print-electronic]. 2016 Sep 9/19/2016; PMID: 27588346, DOI: 10.1021/acschembio.6b00560, ISSN: 1554-8937.
Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A. Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization. J Biomed Opt. 2016 Sep 9/1/2016; 21(9): 90503. PMID: 27626899, PII: 2553360, DOI: 10.1117/1.JBO.21.9.090503, ISSN: 1560-2281.
Adeniji A, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J. Med. Chem [print-electronic]. 2016 Aug 8/25/2016; 59(16): 7431-44. PMID: 27486833, DOI: 10.1021/acs.jmedchem.6b00160, ISSN: 1520-4804.
Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials [print-electronic]. 2016 Jun; 92: 71-80. PMID: 27043768, PMCID: PMC4833621, PII: S0142-9612(16)30049-7, DOI: 10.1016/j.biomaterials.2016.03.028, ISSN: 1878-5905.
Uddin MI, Evans SM, Craft JR, Capozzi ME, McCollum GW, Yang R, Marnett LJ, Uddin MJ, Jayagopal A, Penn JS. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Sci Rep. 2016; 6: 31011. PMID: 27491345, PMCID: PMC4974503, PII: srep31011, DOI: 10.1038/srep31011, ISSN: 2045-2322.
2015
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A. Applications of azo-based probes for imaging retinal hypoxia. ACS Med Chem Lett. 2015 Apr 4/9/2015; 6(4): 445-9. PMID: 25893047, PMCID: PMC4394343, DOI: 10.1021/ml5005206, ISSN: 1948-5875.
Ra H, González-González E, Uddin MJ, King BL, Lee A, Ali-Khan I, Marnett LJ, Tang JY, Contag CH. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia. 2015 Feb; 17(2): 201-7. PMID: 25748239, PMCID: PMC4351298, PII: S1476-5586(14)00199-7, DOI: 10.1016/j.neo.2014.12.009, ISSN: 1476-5586.
2014
Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ. Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. ACS Med Chem Lett. 2014 Nov 11/13/2014; 5(11): 1254-8. PMID: 25408841, PMCID: PMC4233350, DOI: 10.1021/ml500344j, ISSN: 1948-5875.
Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem [print-electronic]. 2014 Jun 6/10/2014; 80: 562-8. PMID: 24832612, PMCID: PMC4401082, PII: S0223-5234(14)00403-6, DOI: 10.1016/j.ejmech.2014.04.074, ISSN: 1768-3254.
Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Med Chem Lett. 2014 Apr 4/10/2014; 5(4): 446-50. PMID: 24900856, PMCID: PMC4027729, DOI: 10.1021/ml400485g, ISSN: 1948-5875.
2013
Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ. The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. ACS Med Chem Lett [print-electronic]. 2013 May 5/9/2013; 4(5): 486-90. PMID: 23687559, PMCID: PMC3654564, DOI: 10.1021/ml400066a, ISSN: 1948-5875.
Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. Bioconjug. Chem [print-electronic]. 2013 Apr 4/17/2013; 24(4): 712-23. PMID: 23488616, PMCID: PMC3630741, DOI: 10.1021/bc300693w, ISSN: 1520-4812.
2011
Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila) [print-electronic]. 2011 Oct; 4(10): 1536-45. PMID: 21900596, PMCID: PMC3214660, PII: 1940-6207.CAPR-11-0120, DOI: 10.1158/1940-6207.CAPR-11-0120, ISSN: 1940-6215.
2010
Uddin MJ, Schulte MI, Maddukuri L, Harp J, Marnett LJ. Semisynthesis of 6-chloropurine-2'-deoxyriboside 5'-dimethoxytrityl 3'-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its use in the synthesis of fluorescently labeled oligonucleotides. Nucleosides Nucleotides Nucleic Acids. 2010 Nov; 29(11): 831-40. PMID: 21128170, PMCID: PMC3019237, PII: 930388354, DOI: 10.1080/15257770.2010.530332, ISSN: 1532-2335.
Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010 May 5/1/2010; 70(9): 3618-27. PMID: 20430759, PMCID: PMC2864539, PII: 70/9/3618, DOI: 10.1158/0008-5472.CAN-09-2664, ISSN: 1538-7445.
Uddin MJ, Smithson DC, Brown KM, Crews BC, Connelly M, Zhu F, Marnett LJ, Guy RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg. Med. Chem. Lett [print-electronic]. 2010 Mar 3/1/2010; 20(5): 1787-91. PMID: 20129783, PMCID: PMC2826502, PII: S0960-894X(10)00011-9, DOI: 10.1016/j.bmcl.2010.01.009, ISSN: 1464-3405.
2009
Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J. Med. Chem. 2009 May 5/14/2009; 52(9): 2846-53. PMID: 19354253, PMCID: PMC2744100, DOI: 10.1021/jm801643b, ISSN: 1520-4804.
Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J.. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals. 2009; 52: 387-93.
2008
Uddin MJ, Marnett LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org. Lett [print-electronic]. 2008 Nov 11/6/2008; 10(21): 4799-801. PMID: 18837556, PMCID: PMC2646678, DOI: 10.1021/ol801904k, ISSN: 1523-7052.
2006
Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B.. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood. 2006; 13: 4059.
2005
Uddin MJ, Rao PN, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg. Med. Chem. Lett. 2005 Jan 1/17/2005; 15(2): 439-42. PMID: 15603969, PII: S0960-894X(04)01291-0, DOI: 10.1016/j.bmcl.2004.10.050, ISSN: 0960-894X.
Uddin MJ, Praveen Rao PN, Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity. Bioorg. Med. Chem. 2005 Jan 1/17/2005; 13(2): 417-24. PMID: 15598562, PII: S0968-0896(04)00791-6, DOI: 10.1016/j.bmc.2004.10.017, ISSN: 0968-0896.
2004
Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Nov 11/18/2004; 47(24): 6108-11. PMID: 15537365, DOI: 10.1021/jm049523y, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. 2004 Nov 11/15/2004; 12(22): 5929-40. PMID: 15498669, PII: S0968-0896(04)00624-8, DOI: 10.1016/j.bmc.2004.08.021, ISSN: 0968-0896.
Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Oct 10/4/2004; 14(19): 4911-4. PMID: 15341950, PII: S0960-894X(04)00919-9, DOI: 10.1016/j.bmcl.2004.07.027, ISSN: 0960-894X.
Rao PN, Uddin MJ, Knaus EE. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Jul 7/29/2004; 47(16): 3972-90. PMID: 15267236, DOI: 10.1021/jm049939b, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Apr 4/19/2004; 14(8): 1953-6. PMID: 15050635, PII: S0960894X04001556, DOI: 10.1016/j.bmcl.2004.01.075, ISSN: 0960-894X.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.. Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett. 2004; 1513.
2003
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg. Med. Chem. 2003 Nov 11/17/2003; 11(23): 5273-80. PMID: 14604691, PII: S0968089603005583, ISSN: 0968-0896.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry. 2003; 40: 861.
2000
Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I.. Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure ?-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity. Synthesis. 2000; 365.
Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I.. Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications. 2000; 6: 113.
Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I.. Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications. 2000; 6: 505.
BOOK CHAPTERS:
1. Vision, Sensing and Analytics: Integrative Approaches. Book Details: Date Published June 6, 2021, Volume 207. Page 416. ISBN 978-3-030-75490-7 (eBook). https://doi.org/10.1007/978-3-030-75490-7, © Springer Nature Switzerland AG 2021.
2. Translational Research in Biophotonics Book Details: Date Published May 1, 2014, Volume PM246. Page 362. ISBN: 9781628410686. https://doi.org/10.1117/3.1002515. © SPIE Press, Bellingham, Washington USA.
FELLOWSHIPS/RECOGNITIONS:
1. Recipient of the Financial Incentives Award from the Vanderbilt University School of Medicine Basic Sciences for securing two nationally competitive research grants.
Inclusive Date: 07/14/2023.
2. Recipient of OMICS Certificate of Recognition for research excellence in molecular imaging of COX-2 in cancer and inflammation at the International Conference on Radiology and Imaging in Chicago-North Shore.
Inclusive Date: 08/14/2013.
3. Recipient of Alberta Heritage Foundation for Medical Research (AHFMR) Post-doctoral Fellowship Award.
Inclusive Dates: 01/01/2002 – 12/31/2004.
4. Recipient of the Japanese Government (MONBUSHO) Graduate Scholarship Award, Department of Education, Japan.
Inclusive Dates: 09/02/1997 – 03/31/2001.
PROFESSIONAL ACTIVITIES:
1. Ad Hoc Grant Reviewer, National Cancer Institute. Imaging Probe & Contrast Agents (IPCA) Study Section.
Inclusive Date: 02/2022 - Present
2. Ad Hoc Grant Reviewer, National Institutes of Health. Radiation Biology and Radiation Therapy (RBRT) Study Section.
Inclusive Date: 06/2025 - Present
3. Ad Hoc Grant Reviewer, North Carolina Biotech Center Interdisciplinary Grant Program.
Inclusive Date: 03/2005 - Present
4. Chairman, Executive Committee, Network for Translational Research (NTR) Chemistry Core, National Institutes of Health.
Inclusive Dates: 02/2012 - 01/2013.
5. Member, Executive Committee, American Association of Cancer Research-American Chemical Society-Joint Meeting on Chemistry in Cancer Research, San Diego.
Inclusive Date: 01/2011 - 01/2012.
MEDIA HIGHLIGHTS IN THE UNITED STATES AND WORLDWIDE:
1. "Uddin receives second Phi Beta Psi national research award." https://medschool.vanderbilt.edu/basic-sciences/2023/08/24/uddin-receives-a-second-phi-beta-psi-national-research-award-2/
Md. Jashim Uddin, research associate professor of biochemistry, has received the Phi Beta Psi national research award for the second year in a row. The award will fund an ongoing project in which Uddin and colleagues are working to develop an improved cancer imaging platform and technique. There has been significant interest within the field of personalized medicine in developing nanotechnologies capable of diagnosis and drug delivery and that can monitor therapeutic response in real time when treating cancer—an unmet medical need today. Strategies for detecting molecular biomarkers associated with the initiation of cancer can facilitate early detection and timely surgical or therapeutic intervention. The discovery that COX-2 is expressed in colon polyps and colon cancers at higher levels than in normal tissue was recapitulated in solid tumors from many other organs. Mechanistic studies indicate that COX-2-generated prostaglandins regulate multiple tumor phenotypes, including proliferation, resistance to apoptosis, cell motility, and angiogenesis, which makes COX-2 an ideal target for molecular imaging and targeted chemotherapy of carcinogenesis.
Along with Uddin, distinguished Professor of Chemistry, Biochemistry, and Pharmacology Lawrence Marnett and colleagues carried out proof-of-principle imaging experiments showing that COX-2 is an ideal target for the delivery of targeted imaging probes and cytotoxic agents to tissues containing elevated levels of the enzyme. Now, the second Phi Beta Psi fund has been awarded to Uddin for the development of a nanotechnology in which disease diagnosis and therapy are combined. Today, the call for personalized medicine demands a new nanoplatform for the simultaneous delivery of both imaging and therapeutic agents to preneoplastic or neoplastic tissues for imaging to be performed not only before or after, but also during a treatment procedure. This project is uniquely built for image-guided intervention of colorectal carcinogenesis.
2. "Uddin receives Phi Beta Psi award to continue development of diagnostic tool for detecting pathological cells". https://medschool.vanderbilt.edu/basic-sciences/2022/12/14/uddin-receives-phi-beta-psi-award-to-continue-development-of-diagnostic-tool-for-detecting-pathological-cells/
Md. Jashim Uddin, research associate professor of biochemistry, has received a 2022 National Project Research Grant from Phi Beta Psi. Uddin was one of six recipients nationally and is the first-ever Vanderbilt faculty member to receive this award. The Phi Beta Psi Sorority is a national civic organization whose members are committed to charitable work and fighting against cancer.
Uddin’s funded project* seeks to advance diagnostic efforts, focusing on the use of a nanotechnology-based probe to enable early detection of colorectal cancer. The goal is to employ nanotechnology in the molecular endoscopic visualization of colon cancer, an aim that builds on recent research he published in ACS Chemical Biology. That paper, published this summer, describes a new probe called fluorocoxib Q, or FQ, which Uddin developed along with fellow researchers in the laboratory of Lawrence Marnett, Mary Geddes Stahlman Professor of Cancer Research and University Distinguished Professor of Biochemistry and Chemistry. The new probe that can be used to distinguish pathological or diseased cells from other, healthy cells, was key to getting the Phi Beta Psi award.
COX-2, the enzyme targeted by the probe, is involved in the synthesis of prostaglandins, which facilitate inflammation. Accordingly, COX-2 is overexpressed in inflamed and neoplastic (abnormally growing) tissues while absent in normal tissues. Thanks to its role in pathogenesis, COX-2 is a promising molecular target for detecting pathological cells and strengthening diagnostic imaging.
Previous work suggests that COX-2 activity is associated with the production of reactive oxygen species, or ROS, which in turn increases the oxidation in the environment. Extending earlier work with COX-2-targeted radiological and optical imaging agents, Uddin and Marnett have now developed a “redox-activatable” imaging agent that specifically binds to COX-2 and is only detectable in the presence of ROS. The team of Vanderbilt scientists evaluated the potential of FQ in both cultured cancer cells and a mouse model of inflammation and established that the use of FQ resulted in higher specificity and less background noise when visualizing pathogenesis compared to other agents.
This new probe is the focus of Uddin’s Phi Beta Psi award, which will allow him to evaluate the use of FQ—encapsulated in a variety of nanoparticles—to use endoscopic optical imaging to detect colonic adenomas, a type of pre-cancerous tumor of the colon. Moreover, he will use the funds to verify that FQ fluoresces specifically in the presence of COX-2 and ROS in colorectal carcinogenesis. The development of FQ, as well as Uddin’s planned work with the nanoparticles, will create a framework for using the presence of COX-2 and ROS as biomarkers of neoplasia in the colon and will facilitate the development of the nanotechnology for the early detection, margin delineation, and surgical removal of colorectal cancer in patients.
*Uddin’s grant proposal was supported by Research Development and Support, which offers proposal development assistance for both private (foundations) and federally funded opportunities. Services include searches for new sponsors, coordination and team building for proposals of any size, content development, and draft review. RDS further supports faculty by building relationships with external sponsors, hosting workshops, and providing guides and language for common proposal requirements. RDS is in the Office of the Vice Provost for Research and Innovation. To learn more about RDS or request services, contact them at rds@vanderbilt.edu.
3. "What’s New in Science?" https://medschool.vanderbilt.edu/basic-sciences/2024/03/07/whats-new-in-science/
Detecting adenomas by colonoscopy remains one of the main preventative measures for colorectal cancer, with almost 100,000 adenomas identified during first-time screenings per year in the U.S. Unfortunately, using white-light colonoscopy—the clinical standard—without probing for a particular molecular marker of adenomas can lead to 30% of lesions going undetected. Md. Jashim Uddin, research associate professor of biochemistry, Larry Marnett, Mary Geddes Stahlman Professor of Cancer Research and university distinguished professor of biochemistry, and colleagues chose to use cyclooxygenase-2 or COX-2, an enzyme that increases inflammation and that is upregulated in preneoplastic lesions and colorectal cancer, as the marker to target when developing a fluorescent imaging agent to improve adenoma detection.
This work, reported in the Journal of Biomedical Optics, signifies an advance in adenoma detection by colonoscopy, which could reduce the number of colorectal cancer cases considering that adenomas, precursor lesions, can be removed during colonoscopies. In 2010, the researchers discovered a fluorescent inhibitor of COX-2 called fluorocoxib A; it was the first COX-2-targeted molecular imaging agent for the in vivo fluorescence imaging of inflammation and cancer and has since been widely used in research in the U.S. and across the globe. Now, the authors sought to forge a path to the clinic and packaged fluorocoxib A into an FDA-approved polymer to improve delivery to the adenomas. Uddin and colleagues administered fluorocoxib A to mice before a colonoscopy, which allowed them to clearly identify colonic adenomas in mice containing elevated levels of COX-2 in the lesions. The colon tissues of normal mice were not illuminated with the fluorescent compound, indicative of the lack of lesions. Pre-dosing the mice with a non-fluorescent inhibitor of COX-2 or with a fluorescent molecule that does not inhibit COX-2 led to minimal labeling of adenomas. Packaging the COX-2 inhibitor in the FDA-approved polymer creates a tractable path for clinical trials that could ultimately impact adenoma detection for the millions who undergo colonoscopies every year across the country. Uddin, M.J., Niitsu, H., Coffey, R.J., Marnett, L.J. (2023). Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas. J Biomed Opt. 2023;28(4):040501.
4. "Potential probe for early ovarian cancer." https://news.vumc.org/2019/06/20/imaging-probe-ovarian-cancer/
Ovarian cancer is the fifth leading cause of cancer death in women and one of the most difficult malignancies to detect at an early stage. Emerging clinical evidence suggests that the enzyme cyclooxygenase-1 (COX-1) contributes significantly to tumorigenesis in ovarian cancer. Thus COX-1 could serve as a novel target for molecular imaging probes to improve early detection and response to treatment. Now in the American Chemical Society journal ACS Omega, Md. Jashim Uddin, PhD, Lawrence Marnett, PhD, and colleagues report the discovery of FDF, a furanone-based novel COX-1 selective inhibitor with adequate properties to enable its use for in vivo imaging. In two distinct animal models of ovarian cancer, xenografts expressing high levels of COX-1 demonstrated targeted uptake of the compound containing the F-18 radioisotope (18F-FDF) compared to tissues expressing low protein levels. This indicates that 18F-FDF may be the first feasible radiotracer validated for targeted PET/CT imaging of neoplastic tissues that express elevated levels of the COX-1 enzyme. The work was featured in the journal as an ACS Editors’ Choice and was supported by grants from the National Institutes of Health (CA128323, CA182850, CA136465, CA089450) and Kay Yow Cancer Fund/V Foundation.
5. "Fluorescent compounds make tumors glow." https://www.sciencedaily.com/releases/2010/04/100429082357.htm
6. "Jashim Uddin has received the prestigious Phi Beta Psi national research award." https://en.ittefaq.com.bd/6159/uddin-receives-a-second-phi-beta-psi-national
7. "Better adenoma detection." https://www.nashvillemedicalnews.com/article/6020/better-adenoma-detection
8. "Challenge puts technology transfer ingenuity on display." https://lab.vanderbilt.edu/jashim-uddin/wp-content/uploads/sites/105/2021/06/%E2%80%98Challenge%E2%80%99-puts-technology-transfer-ingenuity-on-display-VUMC-Reporter-Vanderbilt-University.pdf
9. "Detecting Ovarian cancer earlier." https://cdn.vanderbilt.edu/vu-web/lab-wpcontent/sites/105/2021/05/03213331/1-Discover-Jul312019.pdf
10. "Diagnosing and differentiating cancer at the molecular level." https://cdn.vanderbilt.edu/vu-web/lab-wpcontent/sites/105/2021/05/04152753/CTScan-Nov72011.pdf
TEACHING
Vanderbilt University, Department of Biomedical Engineering
Course Number: BME 3897
Course Syllabus:
The BME 3897 course, is an elective course offered by Vanderbilt Biomedical Engineering Department, focuses on the principles and molecular mechanisms of gene therapy, with emphasis on vector systems, delivery methodologies, and regulation of gene expression and on conceptual and translational approaches to genetic oncology and the development of advanced cancer gene therapies. Integrates case-based and experimental studies to illustrate clinical and biomedical applications in contemporary medicine.
Course Overview:
Title: Gene Therapy Systems for Biomedical Applications (BME 3897)
Credit Hours: 3
Offered: Spring and fall semesters in the 2026 session and beyond
Instructions: BME faculty member Dr. Jashim Uddin, Ph.D.
Prerequisites: Basic knowledge of chemistry, biology, and genetics and introductory biomedical engineering courses with laboratory components is recommended in line with advanced level undergraduate expectations.
Course Features:
a) Emphasis: Active discussion, novel drug development, and clinical translation
b) Essay: Therapeutic proposal or critical essay on gene therapy challenges
c) Lecture: 2 In-class lectures/week, 1.5 hours/lecture, and a total of 30 lectures in 15 weeks/semester
d) Format: Lectures, case studies, quizzes, exams, and group presentations
Course Description:
This course provides upper-level undergraduate students with a comprehensive foundation in the principles and emerging technologies of gene therapy as applied to biomedical challenges. Topics address molecular design, delivery systems, cellular engineering, and clinical translation, emphasizing practical problem-solving in human health contexts. Students will analyze current literature, explore system-level strategies for therapeutic development, and gain insight into regulatory, ethical, and safety considerations driving the field’s adoption. Coursework combines lectures, discussions, and case study experiences.
Course Topics:
Tumor Genetics
1. Introduction to tumor genetics and cancer-gene interactions
2. Innate and adaptive genetics in cancer
3. Antigen recognition and tumor neoantigens.
Cancer Gene Therapy Modalities
4. Principles and mechanisms of checkpoint blockade therapy
5. Cancer neoantigens & personalized gene therapy
6. CAR T cell therapy, design and clinical translation
7. Bispecific T cell engagers and novel cell therapies
8. Tumor vaccines and oncolytic viruses
9. Combination therapies and the future of genetic oncology
Genetic Evasion and Clinical Challenges
10. Mechanisms of tumor gene evasion
11. Gene-related adverse events and toxicities
12. Biomarkers and response assessment in gene therapy
Translational and Clinical Perspectives
13. Clinical implementation and case studies, melanoma, lung, and hematologic malignancies
14. Opportunities and challenges in gene therapy development
15. Conceptualizing next generation gene therapeutic agents
Syllabus Content:
1–2. Foundations
a) Introduction to cancer gene therapy
b) Basic principles of tumor genetics
3–5. The Genetic System in Cancer
a) Genetics in oncology
b) Antigen presentation and neoantigens
c) Genetic surveillance and evasion by tumors
6–8. Gene Therapy Modalities
a) Genetic Checkpoint Inhibitors
b) Clinical Mechanisms of Checkpoint Blockade
c) CAR T Cell Therapy, Concepts and Clinical Trials
9–11. Innovations and Expansion
a) Novel Engineered Cell Therapies (TCR-Ts, BiTEs, NK cells)
b) Tumor Vaccines and Oncolytic Viruses
c) Personalized Gene Therapy Approaches
12–13. Challenges and Complications
a) Mechanisms and Management of Gene-Related Adverse Events
b) Genetic Modulation of Tumor Microenvironment
14-15. Translational and Future Perspectives
a) Biomarkers, Patient Stratification, and Clinical Trial Design
b) Combination Therapies
c) Next-Generation Gene Therapies, Wrap-up and Perspectives
Weekly In-class Lecture Topics:
Week 1–2: Gene Addition (4 lectures)
Lecture 1: Introduction to Gene Therapy
a) History and milestones in gene therapy
b) Early clinical trials and lessons learned
c) Ethical considerations
Lecture 2: Gene Addition Strategies
a) Ex vivo vs in vivo gene addition
b) Case study in gene therapy
Lecture 3: Molecular Basis of Gene Addition
a) Integration vs episomal expression
b) Promoter design and codon optimization
Lecture 4: Clinical Applications of Gene Addition
a) Hemophilia gene therapy case study
b) Cystic fibrosis and muscular dystrophy trials
Week 3–4: Gene Editing (4 lectures)
Lecture 5: Fundamentals of Gene Editing
a) Zinc-finger nucleases, TALENs, CRISPR
b) DNA repair mechanisms: NHEJ and HDR
Lecture 6: CRISPR/Cas9 and Next Generation Editors
a) Base editors, prime editors
b) Off-target effects and mitigation approaches
Lecture 7: Preclinical and Clinical Gene Editing
a) Sickle cell disease
b) Ex vivo bone marrow stem cell editing
Lecture 8: Regulatory and Ethical Challenges in Editing
a) Germline vs somatic editing
b) Ethical case discussions
Week 5–6: Gene Silencing (4 lectures)
Lecture 9: Mechanisms of Gene Silencing
a) RNAi, siRNA, and miRNA
b) Antisense oligonucleotides
Lecture 10: Delivery Systems for Gene Silencing
a) Nanoparticles, conjugates (e.g., GalNAc)
b) Blood-brain barrier penetration attempts
Lecture 11: Clinical Examples of Gene Silencing
a) Patisiran for amyloidosis (siRNA)
b) Spinraza for spinal muscular atrophy (ASO)
Lecture 12: Challenges and Limitations
a) Off-target silencing
b) Immune responses to oligonucleotides
Week 7–8: RNA Therapies (4 lectures)
Lecture 13: mRNA Therapeutics Basics
a) Design, stability, and modification (pseudouridine)
b) Translation efficiency
Lecture 14: Vaccines and mRNA Therapies
a) COVID-19 RNA-based vaccine case study
b) Cancer vaccines (neoantigen-specific mRNA)
Lecture 15: Small RNA Therapies
a) siRNA case studies
b) miRNA mimics and inhibitors
Lecture 16: Delivery and Formulation
a) Lipid nanoparticles
b) Polymers and extracellular vesicle approaches
Week 9–10: Cell Therapy (4 lectures)
Lecture 17: Foundations of Cell Therapy
a) Autologous vs allogeneic cells
b) Stem cell transplant
Lecture 18: CAR-T and TCR-T Cell Therapies
a) Engineering T cells for cancer
b) Clinical outcomes and limitations
Lecture 19: Stem Cell–Based Therapies
a) Gene-corrected hematopoietic stem cells
b) Induced pluripotent stem cell models
Lecture 20: Manufacturing and Scale-Up Challenges
a) GMP requirements
b) Regulatory oversight in cell therapy
Week 11–12: Gene Therapy Delivery Methods (4 lectures)
Lecture 21: In Vivo Gene Therapy Delivery
a) Systemic vs localized delivery
b) Target tissue accessibility
Lecture 22: Ex Vivo Gene Therapy Methodologies
a) Stem cell modification and reinfusion
b) SCID, sickle cell anemia
Lecture 23: Biodistribution and Pharmacokinetics
a) Tracking gene therapies in vivo
b) Imaging methods for biodistribution
Lecture 24: Safety Considerations in Delivery
a) Cytokine storm risks
b) Gene therapy of repeated dosing
Week 13–14: Vectors and Routes of Administration (4 lectures)
Lecture 25: Viral Vectors – Adenovirus and AAV
a) Biology of vectors
b) Applications in liver, muscle, and retina
Lecture 26: Lentivirus and Retrovirus
a) Stable integration
b) Safety and insertional mutagenesis
Lecture 27: Non-Viral Vectors
a) Lipid nanoparticles, electroporation
b) Cell-penetrating peptides
Lecture 28: Routes of Gene Therapy Administration
a) Intravenous, intramuscular, intrathecal
b) Ocular, pulmonary, and mucosal delivery
Week 15: Vectors and Routes of Administration (2 lectures)
Lecture 29: Comparative Case Studies
a) AAV for retinal disorders
b) LNP for mRNA vaccines
c) Challenges with systemic delivery
Lecture 30: Future Perspectives in Gene Therapy Systems
a) Personalized gene editing
b) Artificial intelligence in gene therapy design
c) Ethical and regulatory frontiers
Assignments, Assessments and Grading Plan:
a) Weekly Reading Notes (20%): Students submit a 1-page summary of assigned papers.
b) Case Study Presentations (20%): Each student presents one clinical trial outcome.
c) Midterm Exam (20%): Covers Weeks 1–7 (Lectures 1–14). Short answer + critical analysis questions.
d) Group Project (20%): Design a therapeutic strategy for a chosen genetic disease (includes proposed vector, target, and expected outcomes).
e) Final Exam (20%): Covers full course. Application-based, includes data interpretation, design, and ethics evaluation.
Recommended Textbooks and Literature:
a) Hardy & Khan: Gene Therapy: Prospective Technology Assessment in its Societal Context.
b) Li & Samulski: Gene Therapy: Prospective Approaches to Healthcare.
c) Mason & Dunnett: Stem Cell and Gene-Based Therapy.
d) Strohl: Therapeutic Antibody Engineering (for cell/biologic overlaps).
e) Annual Review of Genetics (journal articles).
f) Nature Reviews Drug Discovery (for recent modality updates)
CONTACT:
Tel: 615-484-8674
E-mail: jashim.uddin@vanderbilt.edu
Institutional Website: https://wag.app.vanderbilt.edu/PublicPage/Faculty/Details/33074
Research Associate Professor, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville TN 37232 USA
Research Associate Professor, Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville TN 37240 USA
NATIONAL AWARDS:
1. National Institutes of Health (NIH), National Research Award, R01 CA260958-01A1 (Role: Principal Investigator/Program Director) 7/05/2021–06/30/2026, $3M.
2. Phi Beta Psi National Research Awards, AWD00001248 and AWD00000652 (Role: Principal Investigator/Program Director) 08/01/2022-08/15/2024, $140K.
RESEARCH INTERESTS:
Jashim's research interests include development of targeted imaging agents for early detection of cancer and discovery of a gene therapy for effective treatment of neoplastic diseases. These projects have been funded by the Phi Beta Psi (PBP) Trust and the National Institutes of Health (NIH) of the United States of America.
MAJOR ACCOMPLISHMENTS:
1. Fluorocoxib A and Its Nanoparticles.
Fluorocoxib A, discovered by Md. Jashim Uddin and colleagues at the Vanderbilt University School of Medicine, is a fluorescent COX-2–selective inhibitor that enables targeted optical imaging of inflammation and cancer in vivo by binding sites of COX-2 overexpression, which is common across inflamed tissues and many solid tumors. It was subsequently formulated for improved delivery, validated across multiple disease models, licensed for commercialization as the XenoLight RediJect COX-2 Probe (Fluorocoxibs), and its platform is highlighted in the Springer medical volume “Imaging Inflammation” (ISBN 978-3-031-23660-0; ISSN 1422-7746).
Scientific discovery: Uddin’s team created Fluorocoxib A (FA) by conjugating a COX-2–inhibitory scaffold with 5-carboxy-X-rhodamine to yield a fluorescent small-molecule that selectively accumulates where COX-2 is induced, enabling noninvasive detection of inflamed and neoplastic tissues in vivo.¿ Follow-on studies from Uddin and collaborators showed FA retains selective COX-2 inhibition at submicromolar concentrations and produces strong lesion-to-background contrast in disease models, including retinal laser–induced choroidal neovascularization and tumor xenografts, with blocking by celecoxib confirming on-target binding.
Nanoparticle formulations: Nanoparticles of fluorocoxib A (FA-NPs) are developed with Vanderbilt bioengineers solubilized poorly water-soluble FA, enabling intravenous dosing, optimal imaging windows at 4–8 h post-injection, and 10-fold higher fluorescence in inflamed or tumor tissue versus normal tissue, supporting translational potential.
Significance for imaging: Because COX-2 is broadly upregulated in inflamed lesions and most solid tumors, FA provides a molecular readout of pathological prostaglandin biology that can aid early detection, staging, and treatment monitoring across oncology and inflammatory diseases.¿ In vivo FA imaging demonstrated high specificity and strong signal-to-background in multiple models (e.g., head and neck tumor xenografts, retinal inflammation), establishing COX-2 as a practical optical target for lesion localization and margin visualization. The FA platform catalyzed development of additional COX-2 probes (e.g., CF3-FA, near-infrared derivatives), expanding applications to endoscopy and image-guided procedures in preclinical and veterinary translational settings.
Licensing and commercialization: The COX-2 fluorescent probe technology from Vanderbilt University (Marnett Lab) has been licensed to Caliper Life Sciences and launched commercially as the XenoLight RediJect COX-2 Probe (Fluorocoxibs) for preclinical imaging on IVIS/Maestro platforms, marking the first market deployment of FA-based COX-2 optical probes. Launch communications emphasized licensing from Vanderbilt and positioned the probe for noninvasive COX-2 detection in oncology and inflammation research, enabling biomarker-guided studies and therapeutic response assessment in live animal models. Caliper’s imaging reagent portfolio (later acquired by PerkinElmer/Revvity) integrated the COX-2 probe with widely used optical systems, fostering broad adoption in preclinical research workflows.
Textbook inclusion of XenoLight: The XenoLight COX-2 probe platform is featured in the medical textbook “Imaging Inflammation” from Springer Nature Switzerland AG (ISBN 978-3-031-23660-0; ISSN 1422-7746), reflecting its recognition as a state-of-the-art molecular imaging approach for inflammatory biology. Vanderbilt’s profile for Uddin explicitly notes the inclusion of the XenoLight probe in the textbook “Imaging Inflammation,” with the Springer DOI listed, linking FA’s translational trajectory from discovery to educational canon in inflammation imaging.
2. Fluorocoxib Q and Its Nanoparticles.
Fluorocoxib Q (FQ) is a groundbreaking molecular probe discovered and developed for the highly specific imaging of cyclooxygenase-2 (COX-2) activity in living cells and animals. The discovery was led by Md Jashim Uddin at Vanderbilt University School of Medicine as an advancement over previous COX-2 imaging agents.
Discovery of Fluorocoxib Q: FQ is the first redox-activatable optical probe specifically designed to target COX-2, an enzyme overexpressed in many inflammatory, premalignant, and malignant tissues. The molecule consists of a nonsteroidal anti-inflammatory drug conjugated to a carboxy-X-rhodamine fluorophore, with a quenching nitroxide group (4-amino-TEMPO) attached. In its default state, FQ has very low fluorescence, making it almost undetectable in normal tissues. Upon entering pathologic tissues, reactive oxygen species (ROS) present in the disease environment reduce FQ to its fluorescent form (FQ-H), which then binds to COX-2, enabling high-contrast, real-time imaging.
Significance of Fluorocoxib Q: Enhanced specificity, FQ activates fluorescence only in redox-rich (ROS-abundant) environments, ensuring signal turns on selectively in diseased tissues with high COX-2 and ROS, minimizing background noise and false positives.
Real-Time In Vivo Imaging: This probe has enabled unprecedented visualization of COX-2 in live animal models, making it a valuable tool for studying inflammation, early cancer progression, and response to therapeutics.
Theranostic Potential: The ability to differentiate between pathologic and normal tissues in real time opens new avenues for targeted diagnosis and image-guided therapy of cancer and inflammatory diseases.
Translational Value: Because of its high metabolic stability and long circulation half-life, FQ accumulates at disease sites, potentially improving both preclinical research and future clinical diagnostics in oncology.
The discovery of Fluorocoxib Q represents a major leap in molecular imaging by allowing highly specific, background-free imaging of COX-2-driven disease processes in living organisms, aiding both research and the development of targeted therapies.
3. Chemocoxib A and Theranostics
Md Jashim Uddin's discovery of Chemocoxib A (CA) represents a breakthrough in the development of theranostic agents for breast cancer, as it is the first validated cytotoxic cyclooxygenase-2 (COX-2) inhibitor used for targeted imaging and treatment of tumors.
Discovery of Chemocoxib A: Chemocoxib A was discovered discovered by Md Jashim Uddin at the Vanderbilt University School of Medicine through a conjugate chemistry approach combining indomethacin (a COX inhibitor) and podophyllotoxin (a potent cytotoxic agent), resulting in a molecule with both high COX-2 selectivity and cytotoxicity. X-ray crystallography confirmed its tight binding to COX-2, and biochemical assays demonstrated that CA selectively inhibits COX-2 and accumulates in COX-2–positive tumor cells, without affecting normal cells lacking COX-2 expression.
Mechanism and Theranostic Platform: Uddin synthesized Chemocoxib A together with the imaging agent fluorocoxib Q (FQ), co-encapsulating both in reactive oxygen species (ROS)-responsive polymeric micellar nanoparticles (FQ-CA-NPs). These nanoparticles enable, a) COX-2-targeted delivery and retention within breast tumors, b) ROS-triggered release of cargo (FQ and CA) in the tumor microenvironmen, c) Fluorescence activation for real-time, image-guided confirmation of drug delivery, d) When administered intravenously in mouse models, FQ-CA-NPs selectively released their therapeutic and imaging cargos within COX-2–expressing breast cancer tissue, allowing direct visualization and significant tumor growth inhibition without systemic toxicity or damage to healthy tissue.
Clinical and Scientific Significance: The discovery of Chemocoxib A is significant milestone because it is the first cytotoxic COX-2 inhibitor validated for in vivo targeted therapy. Its cancer cell–selective cytotoxicity spares normal, COX-2–negative tissues, minimizing side effects. The theranostic platform allows clinicians to both image and treat breast tumors with a single formulation, providing real-time feedback on drug delivery success with high molecular specificity and enabling image-guided optimization of therapeutic regimens. Md Jashim Uddin's Chemocoxib A advances breast cancer theranostics by integrating selective, image-guided therapy and diagnostic capabilities, addressing challenges in both drug targeting and treatment verification.
PATENTS:
2025
Anti-COX-2 nanobodies for endoscopic visualization of colorectal adenomas (US 20250242062 A1, 2025). Disclosed subject matter comprised of methods and composition of nanobodies and their fluorescent conjugates for optical imaging of adenomas of the colon.
Compositions and methods for reducing AKR1C3 in castration-resistant prostate cancer and polycystic ovary syndrome (VU25034P1, 093386-0076-US01). Disclosed subject matter comprised of ligands of E3 ligases conjugated to indomethacin to proteolytically degrade AKR1C3 for the treatment of castration-resistant prostate cancer and polycystic ovary syndrome.
Indomethacin-based degraders of AKR1C3 in castration-resistant prostate cancer (VU41258780 2025). Disclosed subject matter comprised of indomethacin anchored ligands of E3 ligases for the treatment of prostate cancer.
Naproxen-based degraders of AKR1C3 in Prostate Cancer (VU51620495 2025). Disclosed subject matter comprised of naproxen anchored E3 ligase ligands for the treatment of prostate cancer.
2020
Compounds and methods for imaging cancer (US0280543 A1 2018, US 10,792,377 B2 2020). Disclosed materials are diagnostic agents comprised of a radical and a fluorophore moiety. Disclosed technology methods for developing smart probes enable visualization of cells associated with cancer, inflammation, or disorders associated with carcinogenesis.
Composition and method for detecting hypoxia (US 179117 A1 2016, US10,695,446 B2 2020). Disclosed subject matter comprised diagnostic agent conjugated to a hypoxia marker moiety. Disclosed methods and compositions for diagnosing (i.e., by optical imaging) hypoxic cells and/or treating a disorder associated with hypoxia.
2017
Fluorocoxib A loading into ROS-responsive nanoparticles (US0007723 A1 2017, US 10,105,455 B2 2018). Disclosed are compositions and methods for making and using the disclosed compositions. In a further aspect, disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle.
2010
Methods and compositions for diagnostic and therapeutic targeting of COX-2 (US 0254910 A1 2010, WO149456 A2 2007, WO149456 A3 2007, US 8,865,130 B2 2014). Disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also, provided are methods for using the disclosed compositions for diagnosing (i.e. by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activities.
PUBLICATIONS:
2025
Uddin MJ. Advances in Imaging Retinal Inflammation. Experimental Eye Research. 2025, 259, 110537.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman, A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F. Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Micellar Nanoparticles Enables Targeted Visualization of Drug Delivery in Breast Cancer. Molecular Pharmaceutics. 2025, 22, 2392-2401.
Asaduzzaman A, Thompson, CC, Sibai F, Uddin MJ, Application of Ensemble Learning Models in Computer-Aided Diagnosis of Skin Diseases. Neural Computing and Applications. 2025, 37:16735–16751.
Asaduzzaman A, Thompson, C, Sibai F, Uddin MJ, Using The Cancer Genome Atlas from cBioPortal to Develop Genomic Datasets for Machine Learning Assisted Cancer Treatment. BIORXIV/2025/638660
Lobban R, Carroll M, Vest V, Josh T, McCune JTM, Hall S, Yu F, Uddin MJ, Marnett LJ, Duvall CL, Leon M. Bellan LM. COOLING-TRIGGERED RELEASE OF CELECOXIB FROM IMPLANTABLE ALGINATE-SOLUPLUS COMPOSITE DEVICES. ACS Biomaterials Science and Engineering. 2025, 11, 5413-5425.
2024
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin, MT, Nazmin, F, Rahman, MS, Jashim A, Crews, BC, Kingsley, PJ, Marnett, LJ, Duvall, CL, Cook, RS. Polymeric Micellar Nanoparticles Enable Image-guided Drug Delivery in Solid Tumors. BioRxiv. 2024 Jun 6/7/2024; DOI: 10.1101/2024.06.07.598019.
Lo JH, Gbur EF, Francini N, Ma J, Sorets AG, Fletcher RB, Yu F, D'Arcy R, Oltman CG, Uddin MJ, Duvall CL. Synthesis and characterization of chloroquine-modified albumin-binding siRNA-lipid conjugates for improved intracellular delivery and gene silencing in cancer cells. bioRxiv. 2024 Oct 17;. doi: 10.1101/2024.10.14.618042. PubMed PMID: 39464033; PubMed Central PMCID: PMC11507671.
Asaduzzaman A, Thompson CC, Uddin MJ. Improving CADx System Performance for Skin Disease Detection using Ensemble Machine Learning
Models. IEEE TechRxiv, May 02, 2024. DOI: 10.36227/techrxiv.171467652.28972099/v1
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. BioRxiv. 2024 May 5/12/2024; DOI: 10.1101/2024.05.12.593773.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/8/2024; DOI: 10.1021/acsomega.4c03640.
2023
Uddin MJ, Niitsu H, Coffey RJ, Marnett LJ. Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas [letter]. J Biomed Opt [print-electronic]. 2023 Apr; 28(4): 40501. PMID: 37091910, PMCID: PMC10118138, PII: 220308LR, DOI: 10.1117/1.JBO.28.4.040501, ISSN: 1560-2281.
Aleem AM, Kang W, Lin S, Milad M, Kingsley PJ, Crews BC, Uddin MJ, Rouzer CA, Marnett LJ. Ferroptosis Inhibitors Suppress Prostaglandin Synthesis in Lipopolysaccharide-Stimulated Macrophages. ACS Chem Biol [print-electronic]. 2023 Jan 1/13/2023; PMID: 36638351, DOI: 10.1021/acschembio.2c00869, ISSN: 1554-8937.
2022
Uddin MJ, Lo JH, Oltman CG, Crews BC, Huda T, Liu J, Kingsley PJ, Lin S, Milad M, Aleem AM, Asaduzzaman A, McIntyre JO, Duvall CL, Marnett LJ. Discovery of a Redox-Activatable Chemical Probe for Detection of Cyclooxygenase-2 in Cells and Animals. ACS Chem Biol [print-electronic]. 2022 Jul 7/15/2022; 17(7): 1714-22. PMID: 35786843, DOI: 10.1021/acschembio.1c00961, ISSN: 1554-8937.
2021
Winters ND, Bedse G, Astafyev AA, Patrick TA, Altemus M, Morgan AJ, Mukerjee S, Johnson KD, Mahajan VR, Uddin MJ, Kingsley PJ, Centanni SW, Siciliano CA, Samuels DC, Marnett LJ, Winder DG, Patel S. Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. J Clin Invest [print-electronic]. 2021 Jul 7/22/2021; 131(17): PMID: 34292886, PMCID: PMC8409586, PII: e146861, DOI: 10.1172/JCI146861, ISSN: 1558-8238.
2020
Malerba P, Crews BC, Ghebreselasie K, Daniel CK, Jashim E, Aleem AM, Salam RA, Marnett LJ, Uddin MJ. Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1837-42. PMID: 33062161, PMCID: PMC7549111, DOI: 10.1021/acsmedchemlett.9b00280, ISSN: 1948-5875.
Uddin MJ, Xu S, Crews BC, Aleem AM, Ghebreselasie K, Banerjee S, Marnett LJ. Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1881-5. PMID: 33062168, PMCID: PMC7549255, DOI: 10.1021/acsmedchemlett.9b00555, ISSN: 1948-5875.
Uddin MJ, Vemulapalli A, Niitsu H, Crews BC, Oltman CG, Kingsley PJ, Kavanaugh TE, Bedingfield SK, Mcintyre JO, Milad M, Aleem AM, Coffey RJ, Duvall CL, Marnett LJ. Molecular Imaging of Inflammation in Osteoarthritis Using a Water-Soluble Fluorocoxib. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1875-80. PMID: 33062167, PMCID: PMC7549260, DOI: 10.1021/acsmedchemlett.9b00512, ISSN: 1948-5875.
Cekanova M, Pandey S, Olin S, Ryan P, Stokes JE, Hecht S, Martin-Jimenez T, Uddin MJ, Marnett LJ. Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. J Biomed Opt. 2020 Aug; 25(8): PMID: 32860356, PMCID: PMC7456637, PII: JBO-200044R, DOI: 10.1117/1.JBO.25.8.086005, ISSN: 1560-2281.
2019
Bourn J, Rathore K, Donnell R, White W, Uddin MJ, Marnett L, Cekanova M. Detection of carcinogen-induced bladder cancer by fluorocoxib A. BMC Cancer. 2019 Nov 11/27/2019; 19(1): 1152. PMID: 31775672, PMCID: PMC6882158, PII: 10.1186/s12885-019-6366-x, DOI: 10.1186/s12885-019-6366-x, ISSN: 1471-2407.
Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega [print-electronic]. 2019 May 5/31/2019; 4(5): 9251-61. PMID: 31172046, PMCID: PMC6545551, DOI: 10.1021/acsomega.9b01093, ISSN: 2470-1343.
Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ. Conjugated Indomethacin Fluorescent Inhibitors Utilize the Membrane Binding Domain of Cyclooxygenase-2 to Accommodate the Tethered Moiety. J. Biol. Chem. 2019 Apr 4/30/2019; 294(22): 8690-8. PMID: 31000626.
Bourn J, Pandey S, Uddin MJ, Marnett LJ, Cekanova M. Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. Oncotarget. 2019 Jan 1/29/2019; 10(48).
2018
Shaheen SM, Azad AK, Rahman MM, Uddin MJ. A comparative transgene expression study between a protaplex and a rotaplex embedded lipid-nanoparticles in murine derived dendritic cell. J Interdiscipl Nanomed. 2018 Jul 7/10/2018; 0(0).
Cavener VS, Gaulden A, Pennipede D, Jagasia P, Uddin J, Marnett LJ, Patel S. Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Front Neurosci. 2018; 12: 479. PMID: 30108473, PMCID: PMC6080414, DOI: 10.3389/fnins.2018.00479, ISSN: 1662-4548.
2017
Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, Uddin MJ, Plath N, Marnett LJ, Patel S. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biol. Psychiatry [print-electronic]. 2017 Oct 10/1/2017; 82(7): 488-99. PMID: 28438413, PMCID: PMC5585044, PII: S0006-3223(17)31357-4, DOI: 10.1016/j.biopsych.2017.03.002, ISSN: 1873-2402.
Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nat Commun. 2017 Mar 3/28/2017; 8: 14782. PMID: 28348378, PMCID: PMC5379055, PII: ncomms14782, DOI: 10.1038/ncomms14782, ISSN: 2041-1723.
2016
Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron [print-electronic]. 2016 Sep 9/21/2016; 91(6): 1244-52. PMID: 27618677, PII: S0896-6273(16)30509-8, DOI: 10.1016/j.neuron.2016.08.017, ISSN: 1097-4199.
Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ. Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. ACS Chem. Biol [print-electronic]. 2016 Sep 9/19/2016; PMID: 27588346, DOI: 10.1021/acschembio.6b00560, ISSN: 1554-8937.
Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A. Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization. J Biomed Opt. 2016 Sep 9/1/2016; 21(9): 90503. PMID: 27626899, PII: 2553360, DOI: 10.1117/1.JBO.21.9.090503, ISSN: 1560-2281.
Adeniji A, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J. Med. Chem [print-electronic]. 2016 Aug 8/25/2016; 59(16): 7431-44. PMID: 27486833, DOI: 10.1021/acs.jmedchem.6b00160, ISSN: 1520-4804.
Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials [print-electronic]. 2016 Jun; 92: 71-80. PMID: 27043768, PMCID: PMC4833621, PII: S0142-9612(16)30049-7, DOI: 10.1016/j.biomaterials.2016.03.028, ISSN: 1878-5905.
Uddin MI, Evans SM, Craft JR, Capozzi ME, McCollum GW, Yang R, Marnett LJ, Uddin MJ, Jayagopal A, Penn JS. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Sci Rep. 2016; 6: 31011. PMID: 27491345, PMCID: PMC4974503, PII: srep31011, DOI: 10.1038/srep31011, ISSN: 2045-2322.
2015
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A. Applications of azo-based probes for imaging retinal hypoxia. ACS Med Chem Lett. 2015 Apr 4/9/2015; 6(4): 445-9. PMID: 25893047, PMCID: PMC4394343, DOI: 10.1021/ml5005206, ISSN: 1948-5875.
Ra H, González-González E, Uddin MJ, King BL, Lee A, Ali-Khan I, Marnett LJ, Tang JY, Contag CH. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia. 2015 Feb; 17(2): 201-7. PMID: 25748239, PMCID: PMC4351298, PII: S1476-5586(14)00199-7, DOI: 10.1016/j.neo.2014.12.009, ISSN: 1476-5586.
2014
Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ. Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. ACS Med Chem Lett. 2014 Nov 11/13/2014; 5(11): 1254-8. PMID: 25408841, PMCID: PMC4233350, DOI: 10.1021/ml500344j, ISSN: 1948-5875.
Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem [print-electronic]. 2014 Jun 6/10/2014; 80: 562-8. PMID: 24832612, PMCID: PMC4401082, PII: S0223-5234(14)00403-6, DOI: 10.1016/j.ejmech.2014.04.074, ISSN: 1768-3254.
Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Med Chem Lett. 2014 Apr 4/10/2014; 5(4): 446-50. PMID: 24900856, PMCID: PMC4027729, DOI: 10.1021/ml400485g, ISSN: 1948-5875.
2013
Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ. The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. ACS Med Chem Lett [print-electronic]. 2013 May 5/9/2013; 4(5): 486-90. PMID: 23687559, PMCID: PMC3654564, DOI: 10.1021/ml400066a, ISSN: 1948-5875.
Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. Bioconjug. Chem [print-electronic]. 2013 Apr 4/17/2013; 24(4): 712-23. PMID: 23488616, PMCID: PMC3630741, DOI: 10.1021/bc300693w, ISSN: 1520-4812.
2011
Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila) [print-electronic]. 2011 Oct; 4(10): 1536-45. PMID: 21900596, PMCID: PMC3214660, PII: 1940-6207.CAPR-11-0120, DOI: 10.1158/1940-6207.CAPR-11-0120, ISSN: 1940-6215.
2010
Uddin MJ, Schulte MI, Maddukuri L, Harp J, Marnett LJ. Semisynthesis of 6-chloropurine-2'-deoxyriboside 5'-dimethoxytrityl 3'-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its use in the synthesis of fluorescently labeled oligonucleotides. Nucleosides Nucleotides Nucleic Acids. 2010 Nov; 29(11): 831-40. PMID: 21128170, PMCID: PMC3019237, PII: 930388354, DOI: 10.1080/15257770.2010.530332, ISSN: 1532-2335.
Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010 May 5/1/2010; 70(9): 3618-27. PMID: 20430759, PMCID: PMC2864539, PII: 70/9/3618, DOI: 10.1158/0008-5472.CAN-09-2664, ISSN: 1538-7445.
Uddin MJ, Smithson DC, Brown KM, Crews BC, Connelly M, Zhu F, Marnett LJ, Guy RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg. Med. Chem. Lett [print-electronic]. 2010 Mar 3/1/2010; 20(5): 1787-91. PMID: 20129783, PMCID: PMC2826502, PII: S0960-894X(10)00011-9, DOI: 10.1016/j.bmcl.2010.01.009, ISSN: 1464-3405.
2009
Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J. Med. Chem. 2009 May 5/14/2009; 52(9): 2846-53. PMID: 19354253, PMCID: PMC2744100, DOI: 10.1021/jm801643b, ISSN: 1520-4804.
Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J.. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals. 2009; 52: 387-93.
2008
Uddin MJ, Marnett LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org. Lett [print-electronic]. 2008 Nov 11/6/2008; 10(21): 4799-801. PMID: 18837556, PMCID: PMC2646678, DOI: 10.1021/ol801904k, ISSN: 1523-7052.
2006
Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B.. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood. 2006; 13: 4059.
2005
Uddin MJ, Rao PN, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg. Med. Chem. Lett. 2005 Jan 1/17/2005; 15(2): 439-42. PMID: 15603969, PII: S0960-894X(04)01291-0, DOI: 10.1016/j.bmcl.2004.10.050, ISSN: 0960-894X.
Uddin MJ, Praveen Rao PN, Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity. Bioorg. Med. Chem. 2005 Jan 1/17/2005; 13(2): 417-24. PMID: 15598562, PII: S0968-0896(04)00791-6, DOI: 10.1016/j.bmc.2004.10.017, ISSN: 0968-0896.
2004
Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Nov 11/18/2004; 47(24): 6108-11. PMID: 15537365, DOI: 10.1021/jm049523y, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. 2004 Nov 11/15/2004; 12(22): 5929-40. PMID: 15498669, PII: S0968-0896(04)00624-8, DOI: 10.1016/j.bmc.2004.08.021, ISSN: 0968-0896.
Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Oct 10/4/2004; 14(19): 4911-4. PMID: 15341950, PII: S0960-894X(04)00919-9, DOI: 10.1016/j.bmcl.2004.07.027, ISSN: 0960-894X.
Rao PN, Uddin MJ, Knaus EE. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Jul 7/29/2004; 47(16): 3972-90. PMID: 15267236, DOI: 10.1021/jm049939b, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Apr 4/19/2004; 14(8): 1953-6. PMID: 15050635, PII: S0960894X04001556, DOI: 10.1016/j.bmcl.2004.01.075, ISSN: 0960-894X.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.. Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett. 2004; 1513.
2003
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg. Med. Chem. 2003 Nov 11/17/2003; 11(23): 5273-80. PMID: 14604691, PII: S0968089603005583, ISSN: 0968-0896.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry. 2003; 40: 861.
2000
Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I.. Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure ?-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity. Synthesis. 2000; 365.
Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I.. Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications. 2000; 6: 113.
Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I.. Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications. 2000; 6: 505.
BOOK CHAPTERS:
1. Vision, Sensing and Analytics: Integrative Approaches. Book Details: Date Published June 6, 2021, Volume 207. Page 416. ISBN 978-3-030-75490-7 (eBook). https://doi.org/10.1007/978-3-030-75490-7, © Springer Nature Switzerland AG 2021.
2. Translational Research in Biophotonics Book Details: Date Published May 1, 2014, Volume PM246. Page 362. ISBN: 9781628410686. https://doi.org/10.1117/3.1002515. © SPIE Press, Bellingham, Washington USA.
FELLOWSHIPS/RECOGNITIONS:
1. Recipient of the Financial Incentives Award from the Vanderbilt University School of Medicine Basic Sciences for securing two nationally competitive research grants.
Inclusive Date: 07/14/2023.
2. Recipient of OMICS Certificate of Recognition for research excellence in molecular imaging of COX-2 in cancer and inflammation at the International Conference on Radiology and Imaging in Chicago-North Shore.
Inclusive Date: 08/14/2013.
3. Recipient of Alberta Heritage Foundation for Medical Research (AHFMR) Post-doctoral Fellowship Award.
Inclusive Dates: 01/01/2002 – 12/31/2004.
4. Recipient of the Japanese Government (MONBUSHO) Graduate Scholarship Award, Department of Education, Japan.
Inclusive Dates: 09/02/1997 – 03/31/2001.
PROFESSIONAL ACTIVITIES:
1. Ad Hoc Grant Reviewer, National Cancer Institute. Imaging Probe & Contrast Agents (IPCA) Study Section.
Inclusive Date: 02/2022 - Present
2. Ad Hoc Grant Reviewer, National Institutes of Health. Radiation Biology and Radiation Therapy (RBRT) Study Section.
Inclusive Date: 06/2025 - Present
3. Ad Hoc Grant Reviewer, North Carolina Biotech Center Interdisciplinary Grant Program.
Inclusive Date: 03/2005 - Present
4. Chairman, Executive Committee, Network for Translational Research (NTR) Chemistry Core, National Institutes of Health.
Inclusive Dates: 02/2012 - 01/2013.
5. Member, Executive Committee, American Association of Cancer Research-American Chemical Society-Joint Meeting on Chemistry in Cancer Research, San Diego.
Inclusive Date: 01/2011 - 01/2012.
MEDIA HIGHLIGHTS IN THE UNITED STATES AND WORLDWIDE:
1. "Uddin receives second Phi Beta Psi national research award." https://medschool.vanderbilt.edu/basic-sciences/2023/08/24/uddin-receives-a-second-phi-beta-psi-national-research-award-2/
Md. Jashim Uddin, research associate professor of biochemistry, has received the Phi Beta Psi national research award for the second year in a row. The award will fund an ongoing project in which Uddin and colleagues are working to develop an improved cancer imaging platform and technique. There has been significant interest within the field of personalized medicine in developing nanotechnologies capable of diagnosis and drug delivery and that can monitor therapeutic response in real time when treating cancer—an unmet medical need today. Strategies for detecting molecular biomarkers associated with the initiation of cancer can facilitate early detection and timely surgical or therapeutic intervention. The discovery that COX-2 is expressed in colon polyps and colon cancers at higher levels than in normal tissue was recapitulated in solid tumors from many other organs. Mechanistic studies indicate that COX-2-generated prostaglandins regulate multiple tumor phenotypes, including proliferation, resistance to apoptosis, cell motility, and angiogenesis, which makes COX-2 an ideal target for molecular imaging and targeted chemotherapy of carcinogenesis.
Along with Uddin, distinguished Professor of Chemistry, Biochemistry, and Pharmacology Lawrence Marnett and colleagues carried out proof-of-principle imaging experiments showing that COX-2 is an ideal target for the delivery of targeted imaging probes and cytotoxic agents to tissues containing elevated levels of the enzyme. Now, the second Phi Beta Psi fund has been awarded to Uddin for the development of a nanotechnology in which disease diagnosis and therapy are combined. Today, the call for personalized medicine demands a new nanoplatform for the simultaneous delivery of both imaging and therapeutic agents to preneoplastic or neoplastic tissues for imaging to be performed not only before or after, but also during a treatment procedure. This project is uniquely built for image-guided intervention of colorectal carcinogenesis.
2. "Uddin receives Phi Beta Psi award to continue development of diagnostic tool for detecting pathological cells". https://medschool.vanderbilt.edu/basic-sciences/2022/12/14/uddin-receives-phi-beta-psi-award-to-continue-development-of-diagnostic-tool-for-detecting-pathological-cells/
Md. Jashim Uddin, research associate professor of biochemistry, has received a 2022 National Project Research Grant from Phi Beta Psi. Uddin was one of six recipients nationally and is the first-ever Vanderbilt faculty member to receive this award. The Phi Beta Psi Sorority is a national civic organization whose members are committed to charitable work and fighting against cancer.
Uddin’s funded project* seeks to advance diagnostic efforts, focusing on the use of a nanotechnology-based probe to enable early detection of colorectal cancer. The goal is to employ nanotechnology in the molecular endoscopic visualization of colon cancer, an aim that builds on recent research he published in ACS Chemical Biology. That paper, published this summer, describes a new probe called fluorocoxib Q, or FQ, which Uddin developed along with fellow researchers in the laboratory of Lawrence Marnett, Mary Geddes Stahlman Professor of Cancer Research and University Distinguished Professor of Biochemistry and Chemistry. The new probe that can be used to distinguish pathological or diseased cells from other, healthy cells, was key to getting the Phi Beta Psi award.
COX-2, the enzyme targeted by the probe, is involved in the synthesis of prostaglandins, which facilitate inflammation. Accordingly, COX-2 is overexpressed in inflamed and neoplastic (abnormally growing) tissues while absent in normal tissues. Thanks to its role in pathogenesis, COX-2 is a promising molecular target for detecting pathological cells and strengthening diagnostic imaging.
Previous work suggests that COX-2 activity is associated with the production of reactive oxygen species, or ROS, which in turn increases the oxidation in the environment. Extending earlier work with COX-2-targeted radiological and optical imaging agents, Uddin and Marnett have now developed a “redox-activatable” imaging agent that specifically binds to COX-2 and is only detectable in the presence of ROS. The team of Vanderbilt scientists evaluated the potential of FQ in both cultured cancer cells and a mouse model of inflammation and established that the use of FQ resulted in higher specificity and less background noise when visualizing pathogenesis compared to other agents.
This new probe is the focus of Uddin’s Phi Beta Psi award, which will allow him to evaluate the use of FQ—encapsulated in a variety of nanoparticles—to use endoscopic optical imaging to detect colonic adenomas, a type of pre-cancerous tumor of the colon. Moreover, he will use the funds to verify that FQ fluoresces specifically in the presence of COX-2 and ROS in colorectal carcinogenesis. The development of FQ, as well as Uddin’s planned work with the nanoparticles, will create a framework for using the presence of COX-2 and ROS as biomarkers of neoplasia in the colon and will facilitate the development of the nanotechnology for the early detection, margin delineation, and surgical removal of colorectal cancer in patients.
*Uddin’s grant proposal was supported by Research Development and Support, which offers proposal development assistance for both private (foundations) and federally funded opportunities. Services include searches for new sponsors, coordination and team building for proposals of any size, content development, and draft review. RDS further supports faculty by building relationships with external sponsors, hosting workshops, and providing guides and language for common proposal requirements. RDS is in the Office of the Vice Provost for Research and Innovation. To learn more about RDS or request services, contact them at rds@vanderbilt.edu.
3. "What’s New in Science?" https://medschool.vanderbilt.edu/basic-sciences/2024/03/07/whats-new-in-science/
Detecting adenomas by colonoscopy remains one of the main preventative measures for colorectal cancer, with almost 100,000 adenomas identified during first-time screenings per year in the U.S. Unfortunately, using white-light colonoscopy—the clinical standard—without probing for a particular molecular marker of adenomas can lead to 30% of lesions going undetected. Md. Jashim Uddin, research associate professor of biochemistry, Larry Marnett, Mary Geddes Stahlman Professor of Cancer Research and university distinguished professor of biochemistry, and colleagues chose to use cyclooxygenase-2 or COX-2, an enzyme that increases inflammation and that is upregulated in preneoplastic lesions and colorectal cancer, as the marker to target when developing a fluorescent imaging agent to improve adenoma detection.
This work, reported in the Journal of Biomedical Optics, signifies an advance in adenoma detection by colonoscopy, which could reduce the number of colorectal cancer cases considering that adenomas, precursor lesions, can be removed during colonoscopies. In 2010, the researchers discovered a fluorescent inhibitor of COX-2 called fluorocoxib A; it was the first COX-2-targeted molecular imaging agent for the in vivo fluorescence imaging of inflammation and cancer and has since been widely used in research in the U.S. and across the globe. Now, the authors sought to forge a path to the clinic and packaged fluorocoxib A into an FDA-approved polymer to improve delivery to the adenomas. Uddin and colleagues administered fluorocoxib A to mice before a colonoscopy, which allowed them to clearly identify colonic adenomas in mice containing elevated levels of COX-2 in the lesions. The colon tissues of normal mice were not illuminated with the fluorescent compound, indicative of the lack of lesions. Pre-dosing the mice with a non-fluorescent inhibitor of COX-2 or with a fluorescent molecule that does not inhibit COX-2 led to minimal labeling of adenomas. Packaging the COX-2 inhibitor in the FDA-approved polymer creates a tractable path for clinical trials that could ultimately impact adenoma detection for the millions who undergo colonoscopies every year across the country. Uddin, M.J., Niitsu, H., Coffey, R.J., Marnett, L.J. (2023). Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas. J Biomed Opt. 2023;28(4):040501.
4. "Potential probe for early ovarian cancer." https://news.vumc.org/2019/06/20/imaging-probe-ovarian-cancer/
Ovarian cancer is the fifth leading cause of cancer death in women and one of the most difficult malignancies to detect at an early stage. Emerging clinical evidence suggests that the enzyme cyclooxygenase-1 (COX-1) contributes significantly to tumorigenesis in ovarian cancer. Thus COX-1 could serve as a novel target for molecular imaging probes to improve early detection and response to treatment. Now in the American Chemical Society journal ACS Omega, Md. Jashim Uddin, PhD, Lawrence Marnett, PhD, and colleagues report the discovery of FDF, a furanone-based novel COX-1 selective inhibitor with adequate properties to enable its use for in vivo imaging. In two distinct animal models of ovarian cancer, xenografts expressing high levels of COX-1 demonstrated targeted uptake of the compound containing the F-18 radioisotope (18F-FDF) compared to tissues expressing low protein levels. This indicates that 18F-FDF may be the first feasible radiotracer validated for targeted PET/CT imaging of neoplastic tissues that express elevated levels of the COX-1 enzyme. The work was featured in the journal as an ACS Editors’ Choice and was supported by grants from the National Institutes of Health (CA128323, CA182850, CA136465, CA089450) and Kay Yow Cancer Fund/V Foundation.
5. "Fluorescent compounds make tumors glow." https://www.sciencedaily.com/releases/2010/04/100429082357.htm
6. "Jashim Uddin has received the prestigious Phi Beta Psi national research award." https://en.ittefaq.com.bd/6159/uddin-receives-a-second-phi-beta-psi-national
7. "Better adenoma detection." https://www.nashvillemedicalnews.com/article/6020/better-adenoma-detection
8. "Challenge puts technology transfer ingenuity on display." https://lab.vanderbilt.edu/jashim-uddin/wp-content/uploads/sites/105/2021/06/%E2%80%98Challenge%E2%80%99-puts-technology-transfer-ingenuity-on-display-VUMC-Reporter-Vanderbilt-University.pdf
9. "Detecting Ovarian cancer earlier." https://cdn.vanderbilt.edu/vu-web/lab-wpcontent/sites/105/2021/05/03213331/1-Discover-Jul312019.pdf
10. "Diagnosing and differentiating cancer at the molecular level." https://cdn.vanderbilt.edu/vu-web/lab-wpcontent/sites/105/2021/05/04152753/CTScan-Nov72011.pdf
TEACHING
Vanderbilt University, Department of Biomedical Engineering
Course Number: BME 3897
Course Syllabus:
The BME 3897 course, is an elective course offered by Vanderbilt Biomedical Engineering Department, focuses on the principles and molecular mechanisms of gene therapy, with emphasis on vector systems, delivery methodologies, and regulation of gene expression and on conceptual and translational approaches to genetic oncology and the development of advanced cancer gene therapies. Integrates case-based and experimental studies to illustrate clinical and biomedical applications in contemporary medicine.
Course Overview:
Title: Gene Therapy Systems for Biomedical Applications (BME 3897)
Credit Hours: 3
Offered: Spring and fall semesters in the 2026 session and beyond
Instructions: BME faculty member Dr. Jashim Uddin, Ph.D.
Prerequisites: Basic knowledge of chemistry, biology, and genetics and introductory biomedical engineering courses with laboratory components is recommended in line with advanced level undergraduate expectations.
Course Features:
a) Emphasis: Active discussion, novel drug development, and clinical translation
b) Essay: Therapeutic proposal or critical essay on gene therapy challenges
c) Lecture: 2 In-class lectures/week, 1.5 hours/lecture, and a total of 30 lectures in 15 weeks/semester
d) Format: Lectures, case studies, quizzes, exams, and group presentations
Course Description:
This course provides upper-level undergraduate students with a comprehensive foundation in the principles and emerging technologies of gene therapy as applied to biomedical challenges. Topics address molecular design, delivery systems, cellular engineering, and clinical translation, emphasizing practical problem-solving in human health contexts. Students will analyze current literature, explore system-level strategies for therapeutic development, and gain insight into regulatory, ethical, and safety considerations driving the field’s adoption. Coursework combines lectures, discussions, and case study experiences.
Course Topics:
Tumor Genetics
1. Introduction to tumor genetics and cancer-gene interactions
2. Innate and adaptive genetics in cancer
3. Antigen recognition and tumor neoantigens.
Cancer Gene Therapy Modalities
4. Principles and mechanisms of checkpoint blockade therapy
5. Cancer neoantigens & personalized gene therapy
6. CAR T cell therapy, design and clinical translation
7. Bispecific T cell engagers and novel cell therapies
8. Tumor vaccines and oncolytic viruses
9. Combination therapies and the future of genetic oncology
Genetic Evasion and Clinical Challenges
10. Mechanisms of tumor gene evasion
11. Gene-related adverse events and toxicities
12. Biomarkers and response assessment in gene therapy
Translational and Clinical Perspectives
13. Clinical implementation and case studies, melanoma, lung, and hematologic malignancies
14. Opportunities and challenges in gene therapy development
15. Conceptualizing next generation gene therapeutic agents
Syllabus Content:
1–2. Foundations
a) Introduction to cancer gene therapy
b) Basic principles of tumor genetics
3–5. The Genetic System in Cancer
a) Genetics in oncology
b) Antigen presentation and neoantigens
c) Genetic surveillance and evasion by tumors
6–8. Gene Therapy Modalities
a) Genetic Checkpoint Inhibitors
b) Clinical Mechanisms of Checkpoint Blockade
c) CAR T Cell Therapy, Concepts and Clinical Trials
9–11. Innovations and Expansion
a) Novel Engineered Cell Therapies (TCR-Ts, BiTEs, NK cells)
b) Tumor Vaccines and Oncolytic Viruses
c) Personalized Gene Therapy Approaches
12–13. Challenges and Complications
a) Mechanisms and Management of Gene-Related Adverse Events
b) Genetic Modulation of Tumor Microenvironment
14-15. Translational and Future Perspectives
a) Biomarkers, Patient Stratification, and Clinical Trial Design
b) Combination Therapies
c) Next-Generation Gene Therapies, Wrap-up and Perspectives
Weekly In-class Lecture Topics:
Week 1–2: Gene Addition (4 lectures)
Lecture 1: Introduction to Gene Therapy
a) History and milestones in gene therapy
b) Early clinical trials and lessons learned
c) Ethical considerations
Lecture 2: Gene Addition Strategies
a) Ex vivo vs in vivo gene addition
b) Case study in gene therapy
Lecture 3: Molecular Basis of Gene Addition
a) Integration vs episomal expression
b) Promoter design and codon optimization
Lecture 4: Clinical Applications of Gene Addition
a) Hemophilia gene therapy case study
b) Cystic fibrosis and muscular dystrophy trials
Week 3–4: Gene Editing (4 lectures)
Lecture 5: Fundamentals of Gene Editing
a) Zinc-finger nucleases, TALENs, CRISPR
b) DNA repair mechanisms: NHEJ and HDR
Lecture 6: CRISPR/Cas9 and Next Generation Editors
a) Base editors, prime editors
b) Off-target effects and mitigation approaches
Lecture 7: Preclinical and Clinical Gene Editing
a) Sickle cell disease
b) Ex vivo bone marrow stem cell editing
Lecture 8: Regulatory and Ethical Challenges in Editing
a) Germline vs somatic editing
b) Ethical case discussions
Week 5–6: Gene Silencing (4 lectures)
Lecture 9: Mechanisms of Gene Silencing
a) RNAi, siRNA, and miRNA
b) Antisense oligonucleotides
Lecture 10: Delivery Systems for Gene Silencing
a) Nanoparticles, conjugates (e.g., GalNAc)
b) Blood-brain barrier penetration attempts
Lecture 11: Clinical Examples of Gene Silencing
a) Patisiran for amyloidosis (siRNA)
b) Spinraza for spinal muscular atrophy (ASO)
Lecture 12: Challenges and Limitations
a) Off-target silencing
b) Immune responses to oligonucleotides
Week 7–8: RNA Therapies (4 lectures)
Lecture 13: mRNA Therapeutics Basics
a) Design, stability, and modification (pseudouridine)
b) Translation efficiency
Lecture 14: Vaccines and mRNA Therapies
a) COVID-19 RNA-based vaccine case study
b) Cancer vaccines (neoantigen-specific mRNA)
Lecture 15: Small RNA Therapies
a) siRNA case studies
b) miRNA mimics and inhibitors
Lecture 16: Delivery and Formulation
a) Lipid nanoparticles
b) Polymers and extracellular vesicle approaches
Week 9–10: Cell Therapy (4 lectures)
Lecture 17: Foundations of Cell Therapy
a) Autologous vs allogeneic cells
b) Stem cell transplant
Lecture 18: CAR-T and TCR-T Cell Therapies
a) Engineering T cells for cancer
b) Clinical outcomes and limitations
Lecture 19: Stem Cell–Based Therapies
a) Gene-corrected hematopoietic stem cells
b) Induced pluripotent stem cell models
Lecture 20: Manufacturing and Scale-Up Challenges
a) GMP requirements
b) Regulatory oversight in cell therapy
Week 11–12: Gene Therapy Delivery Methods (4 lectures)
Lecture 21: In Vivo Gene Therapy Delivery
a) Systemic vs localized delivery
b) Target tissue accessibility
Lecture 22: Ex Vivo Gene Therapy Methodologies
a) Stem cell modification and reinfusion
b) SCID, sickle cell anemia
Lecture 23: Biodistribution and Pharmacokinetics
a) Tracking gene therapies in vivo
b) Imaging methods for biodistribution
Lecture 24: Safety Considerations in Delivery
a) Cytokine storm risks
b) Gene therapy of repeated dosing
Week 13–14: Vectors and Routes of Administration (4 lectures)
Lecture 25: Viral Vectors – Adenovirus and AAV
a) Biology of vectors
b) Applications in liver, muscle, and retina
Lecture 26: Lentivirus and Retrovirus
a) Stable integration
b) Safety and insertional mutagenesis
Lecture 27: Non-Viral Vectors
a) Lipid nanoparticles, electroporation
b) Cell-penetrating peptides
Lecture 28: Routes of Gene Therapy Administration
a) Intravenous, intramuscular, intrathecal
b) Ocular, pulmonary, and mucosal delivery
Week 15: Vectors and Routes of Administration (2 lectures)
Lecture 29: Comparative Case Studies
a) AAV for retinal disorders
b) LNP for mRNA vaccines
c) Challenges with systemic delivery
Lecture 30: Future Perspectives in Gene Therapy Systems
a) Personalized gene editing
b) Artificial intelligence in gene therapy design
c) Ethical and regulatory frontiers
Assignments, Assessments and Grading Plan:
a) Weekly Reading Notes (20%): Students submit a 1-page summary of assigned papers.
b) Case Study Presentations (20%): Each student presents one clinical trial outcome.
c) Midterm Exam (20%): Covers Weeks 1–7 (Lectures 1–14). Short answer + critical analysis questions.
d) Group Project (20%): Design a therapeutic strategy for a chosen genetic disease (includes proposed vector, target, and expected outcomes).
e) Final Exam (20%): Covers full course. Application-based, includes data interpretation, design, and ethics evaluation.
Recommended Textbooks and Literature:
a) Hardy & Khan: Gene Therapy: Prospective Technology Assessment in its Societal Context.
b) Li & Samulski: Gene Therapy: Prospective Approaches to Healthcare.
c) Mason & Dunnett: Stem Cell and Gene-Based Therapy.
d) Strohl: Therapeutic Antibody Engineering (for cell/biologic overlaps).
e) Annual Review of Genetics (journal articles).
f) Nature Reviews Drug Discovery (for recent modality updates)
CONTACT:
Tel: 615-484-8674
E-mail: jashim.uddin@vanderbilt.edu
Institutional Website: https://wag.app.vanderbilt.edu/PublicPage/Faculty/Details/33074
Research Keywords
Molecular imaging of carcinogenesis; gene therapy of neoplastic diseases
Publications
Lobban R, Carroll M, Vest V, McCune JT, Hall S, Yu F, Uddin MJ, Marnett LJ, Duvall CL, Bellan LM. Cooling-Triggered Release of Celecoxib from Implantable Alginate-Soluplus Composite Devices. ACS Biomater Sci Eng [print-electronic]. 2025 Sep 9/8/2025; 11(9): 5413-25. PMID: 40854239, PMCID: PMC12421509, DOI: 10.1021/acsbiomaterials.5c00867, ISSN: 2373-9878.
Uddin MJ. Advances in imaging retinal inflammation. Exp Eye Res [print-electronic]. 2025 Jul 7/23/2025; 259: 110537. PMID: 40712880, PII: S0014-4835(25)00308-2, DOI: 10.1016/j.exer.2025.110537, ISSN: 1096-0007.
Advances in imaging retinal inflammation. Experimental eye research. 2025 Jul 7/1/2025.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F, Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Mol Pharm [print-electronic]. 2025 May 5/5/2025; 22(5): 2392-401. PMID: 40257460, PMCID: PMC12056698, DOI: 10.1021/acs.molpharmaceut.4c00695, ISSN: 1543-8392.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F, Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Mol Pharm [print-electronic]. 2025 Apr 4/21/2025; PMID: 40257460, DOI: 10.1021/acs.molpharmaceut.4c00695, ISSN: 1543-8392.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/30/2024; 9(30): 32853-63. PMID: 39100361, PMCID: PMC11292652, DOI: 10.1021/acsomega.4c03640, ISSN: 2470-1343.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/8/2024; DOI: 10.1021/acsomega.4c03640.
Uddin MJ, et al. Polymeric Micellar Nanoparticles Enable Image-guided Drug Delivery in Solid Tumors. BioRxiv. 2024 Jun 6/7/2024; DOI: 10.1101/2024.06.07.598019.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. BioRxiv. 2024 May 5/12/2024; DOI: 10.1101/2024.05.12.593773.
Uddin MJ, Niitsu H, Coffey RJ, Marnett LJ. Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas [letter]. J Biomed Opt [print-electronic]. 2023 Apr; 28(4): 40501. PMID: 37091910, PMCID: PMC10118138, PII: 220308LR, DOI: 10.1117/1.JBO.28.4.040501, ISSN: 1560-2281.
Aleem AM, Kang W, Lin S, Milad M, Kingsley PJ, Crews BC, Uddin MJ, Rouzer CA, Marnett LJ. Ferroptosis Inhibitors Suppress Prostaglandin Synthesis in Lipopolysaccharide-Stimulated Macrophages. ACS Chem Biol [print-electronic]. 2023 Jan 1/13/2023; PMID: 36638351, DOI: 10.1021/acschembio.2c00869, ISSN: 1554-8937.
Uddin MJ, Lo JH, Oltman CG, Crews BC, Huda T, Liu J, Kingsley PJ, Lin S, Milad M, Aleem AM, Asaduzzaman A, McIntyre JO, Duvall CL, Marnett LJ. Discovery of a Redox-Activatable Chemical Probe for Detection of Cyclooxygenase-2 in Cells and Animals. ACS Chem Biol [print-electronic]. 2022 Jul 7/15/2022; 17(7): 1714-22. PMID: 35786843, DOI: 10.1021/acschembio.1c00961, ISSN: 1554-8937.
Winters ND, Bedse G, Astafyev AA, Patrick TA, Altemus M, Morgan AJ, Mukerjee S, Johnson KD, Mahajan VR, Uddin MJ, Kingsley PJ, Centanni SW, Siciliano CA, Samuels DC, Marnett LJ, Winder DG, Patel S. Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. J Clin Invest [print-electronic]. 2021 Jul 7/22/2021; 131(17): PMID: 34292886, PMCID: PMC8409586, PII: e146861, DOI: 10.1172/JCI146861, ISSN: 1558-8238.
Malerba P, Crews BC, Ghebreselasie K, Daniel CK, Jashim E, Aleem AM, Salam RA, Marnett LJ, Uddin MJ. Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1837-42. PMID: 33062161, PMCID: PMC7549111, DOI: 10.1021/acsmedchemlett.9b00280, ISSN: 1948-5875.
Uddin MJ, Xu S, Crews BC, Aleem AM, Ghebreselasie K, Banerjee S, Marnett LJ. Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1881-5. PMID: 33062168, PMCID: PMC7549255, DOI: 10.1021/acsmedchemlett.9b00555, ISSN: 1948-5875.
Uddin MJ, Vemulapalli A, Niitsu H, Crews BC, Oltman CG, Kingsley PJ, Kavanaugh TE, Bedingfield SK, Mcintyre JO, Milad M, Aleem AM, Coffey RJ, Duvall CL, Marnett LJ. Molecular Imaging of Inflammation in Osteoarthritis Using a Water-Soluble Fluorocoxib. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1875-80. PMID: 33062167, PMCID: PMC7549260, DOI: 10.1021/acsmedchemlett.9b00512, ISSN: 1948-5875.
Cekanova M, Pandey S, Olin S, Ryan P, Stokes JE, Hecht S, Martin-Jimenez T, Uddin MJ, Marnett LJ. Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. J Biomed Opt. 2020 Aug; 25(8): PMID: 32860356, PMCID: PMC7456637, PII: JBO-200044R, DOI: 10.1117/1.JBO.25.8.086005, ISSN: 1560-2281.
Bourn J, Rathore K, Donnell R, White W, Uddin MJ, Marnett L, Cekanova M. Detection of carcinogen-induced bladder cancer by fluorocoxib A. BMC Cancer. 2019 Nov 11/27/2019; 19(1): 1152. PMID: 31775672, PMCID: PMC6882158, PII: 10.1186/s12885-019-6366-x, DOI: 10.1186/s12885-019-6366-x, ISSN: 1471-2407.
Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega [print-electronic]. 2019 May 5/31/2019; 4(5): 9251-61. PMID: 31172046, PMCID: PMC6545551, DOI: 10.1021/acsomega.9b01093, ISSN: 2470-1343.
Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ. Conjugated Indomethacin Fluorescent Inhibitors Utilize the Membrane Binding Domain of Cyclooxygenase-2 to Accommodate the Tethered Moiety. J. Biol. Chem. 2019 Apr 4/30/2019; 294(22): 8690-8. PMID: 31000626.
Bourn J, Pandey S, Uddin MJ, Marnett LJ, Cekanova M. Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. Oncotarget. 2019 Jan 1/29/2019; 10(48).
Shaheen SM, Azad AK, Rahman MM, Uddin MJ. A comparative transgene expression study between a protaplex and a rotaplex embedded lipid-nanoparticles in murine derived dendritic cell. J Interdiscipl Nanomed. 2018 Jul 7/10/2018; 0(0).
Cavener VS, Gaulden A, Pennipede D, Jagasia P, Uddin J, Marnett LJ, Patel S. Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Front Neurosci. 2018; 12: 479. PMID: 30108473, PMCID: PMC6080414, DOI: 10.3389/fnins.2018.00479, ISSN: 1662-4548.
Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, Uddin MJ, Plath N, Marnett LJ, Patel S. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biol. Psychiatry [print-electronic]. 2017 Oct 10/1/2017; 82(7): 488-99. PMID: 28438413, PMCID: PMC5585044, PII: S0006-3223(17)31357-4, DOI: 10.1016/j.biopsych.2017.03.002, ISSN: 1873-2402.
Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nat Commun. 2017 Mar 3/28/2017; 8: 14782. PMID: 28348378, PMCID: PMC5379055, PII: ncomms14782, DOI: 10.1038/ncomms14782, ISSN: 2041-1723.
Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron [print-electronic]. 2016 Sep 9/21/2016; 91(6): 1244-52. PMID: 27618677, PII: S0896-6273(16)30509-8, DOI: 10.1016/j.neuron.2016.08.017, ISSN: 1097-4199.
Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ. Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. ACS Chem. Biol [print-electronic]. 2016 Sep 9/19/2016; PMID: 27588346, DOI: 10.1021/acschembio.6b00560, ISSN: 1554-8937.
Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A. Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization. J Biomed Opt. 2016 Sep 9/1/2016; 21(9): 90503. PMID: 27626899, PII: 2553360, DOI: 10.1117/1.JBO.21.9.090503, ISSN: 1560-2281.
Adeniji A, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J. Med. Chem [print-electronic]. 2016 Aug 8/25/2016; 59(16): 7431-44. PMID: 27486833, DOI: 10.1021/acs.jmedchem.6b00160, ISSN: 1520-4804.
Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials [print-electronic]. 2016 Jun; 92: 71-80. PMID: 27043768, PMCID: PMC4833621, PII: S0142-9612(16)30049-7, DOI: 10.1016/j.biomaterials.2016.03.028, ISSN: 1878-5905.
Uddin MI, Evans SM, Craft JR, Capozzi ME, McCollum GW, Yang R, Marnett LJ, Uddin MJ, Jayagopal A, Penn JS. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Sci Rep. 2016; 6: 31011. PMID: 27491345, PMCID: PMC4974503, PII: srep31011, DOI: 10.1038/srep31011, ISSN: 2045-2322.
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A. Applications of azo-based probes for imaging retinal hypoxia. ACS Med Chem Lett. 2015 Apr 4/9/2015; 6(4): 445-9. PMID: 25893047, PMCID: PMC4394343, DOI: 10.1021/ml5005206, ISSN: 1948-5875.
Ra H, González-González E, Uddin MJ, King BL, Lee A, Ali-Khan I, Marnett LJ, Tang JY, Contag CH. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia. 2015 Feb; 17(2): 201-7. PMID: 25748239, PMCID: PMC4351298, PII: S1476-5586(14)00199-7, DOI: 10.1016/j.neo.2014.12.009, ISSN: 1476-5586.
Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ. Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. ACS Med Chem Lett. 2014 Nov 11/13/2014; 5(11): 1254-8. PMID: 25408841, PMCID: PMC4233350, DOI: 10.1021/ml500344j, ISSN: 1948-5875.
Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem [print-electronic]. 2014 Jun 6/10/2014; 80: 562-8. PMID: 24832612, PMCID: PMC4401082, PII: S0223-5234(14)00403-6, DOI: 10.1016/j.ejmech.2014.04.074, ISSN: 1768-3254.
Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Med Chem Lett. 2014 Apr 4/10/2014; 5(4): 446-50. PMID: 24900856, PMCID: PMC4027729, DOI: 10.1021/ml400485g, ISSN: 1948-5875.
Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ. The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. ACS Med Chem Lett [print-electronic]. 2013 May 5/9/2013; 4(5): 486-90. PMID: 23687559, PMCID: PMC3654564, DOI: 10.1021/ml400066a, ISSN: 1948-5875.
Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. Bioconjug. Chem [print-electronic]. 2013 Apr 4/17/2013; 24(4): 712-23. PMID: 23488616, PMCID: PMC3630741, DOI: 10.1021/bc300693w, ISSN: 1520-4812.
Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila) [print-electronic]. 2011 Oct; 4(10): 1536-45. PMID: 21900596, PMCID: PMC3214660, PII: 1940-6207.CAPR-11-0120, DOI: 10.1158/1940-6207.CAPR-11-0120, ISSN: 1940-6215.
Uddin MJ, Schulte MI, Maddukuri L, Harp J, Marnett LJ. Semisynthesis of 6-chloropurine-2'-deoxyriboside 5'-dimethoxytrityl 3'-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its use in the synthesis of fluorescently labeled oligonucleotides. Nucleosides Nucleotides Nucleic Acids. 2010 Nov; 29(11): 831-40. PMID: 21128170, PMCID: PMC3019237, PII: 930388354, DOI: 10.1080/15257770.2010.530332, ISSN: 1532-2335.
Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010 May 5/1/2010; 70(9): 3618-27. PMID: 20430759, PMCID: PMC2864539, PII: 70/9/3618, DOI: 10.1158/0008-5472.CAN-09-2664, ISSN: 1538-7445.
Uddin MJ, Smithson DC, Brown KM, Crews BC, Connelly M, Zhu F, Marnett LJ, Guy RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg. Med. Chem. Lett [print-electronic]. 2010 Mar 3/1/2010; 20(5): 1787-91. PMID: 20129783, PMCID: PMC2826502, PII: S0960-894X(10)00011-9, DOI: 10.1016/j.bmcl.2010.01.009, ISSN: 1464-3405.
Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J. Med. Chem. 2009 May 5/14/2009; 52(9): 2846-53. PMID: 19354253, PMCID: PMC2744100, DOI: 10.1021/jm801643b, ISSN: 1520-4804.
Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J.. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals. 2009; 52: 387-93.
Uddin MJ, Marnett LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org. Lett [print-electronic]. 2008 Nov 11/6/2008; 10(21): 4799-801. PMID: 18837556, PMCID: PMC2646678, DOI: 10.1021/ol801904k, ISSN: 1523-7052.
Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B.. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood. 2006; 13: 4059.
Uddin MJ, Rao PN, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg. Med. Chem. Lett. 2005 Jan 1/17/2005; 15(2): 439-42. PMID: 15603969, PII: S0960-894X(04)01291-0, DOI: 10.1016/j.bmcl.2004.10.050, ISSN: 0960-894X.
Uddin MJ, Praveen Rao PN, Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity. Bioorg. Med. Chem. 2005 Jan 1/17/2005; 13(2): 417-24. PMID: 15598562, PII: S0968-0896(04)00791-6, DOI: 10.1016/j.bmc.2004.10.017, ISSN: 0968-0896.
Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Nov 11/18/2004; 47(24): 6108-11. PMID: 15537365, DOI: 10.1021/jm049523y, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. 2004 Nov 11/15/2004; 12(22): 5929-40. PMID: 15498669, PII: S0968-0896(04)00624-8, DOI: 10.1016/j.bmc.2004.08.021, ISSN: 0968-0896.
Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Oct 10/4/2004; 14(19): 4911-4. PMID: 15341950, PII: S0960-894X(04)00919-9, DOI: 10.1016/j.bmcl.2004.07.027, ISSN: 0960-894X.
Rao PN, Uddin MJ, Knaus EE. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Jul 7/29/2004; 47(16): 3972-90. PMID: 15267236, DOI: 10.1021/jm049939b, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Apr 4/19/2004; 14(8): 1953-6. PMID: 15050635, PII: S0960894X04001556, DOI: 10.1016/j.bmcl.2004.01.075, ISSN: 0960-894X.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.. Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett. 2004; 1513.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg. Med. Chem. 2003 Nov 11/17/2003; 11(23): 5273-80. PMID: 14604691, PII: S0968089603005583, ISSN: 0968-0896.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry. 2003; 40: 861.
Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I.. Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure ?-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity. Synthesis. 2000; 365.
Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I.. Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications. 2000; 6: 113.
Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I.. Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications. 2000; 6: 505.
Uddin MJ. Advances in imaging retinal inflammation. Exp Eye Res [print-electronic]. 2025 Jul 7/23/2025; 259: 110537. PMID: 40712880, PII: S0014-4835(25)00308-2, DOI: 10.1016/j.exer.2025.110537, ISSN: 1096-0007.
Advances in imaging retinal inflammation. Experimental eye research. 2025 Jul 7/1/2025.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F, Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Mol Pharm [print-electronic]. 2025 May 5/5/2025; 22(5): 2392-401. PMID: 40257460, PMCID: PMC12056698, DOI: 10.1021/acs.molpharmaceut.4c00695, ISSN: 1543-8392.
Uddin MJ, Lo JH, Gupta MK, Werfel TA, Asaduzzaman A, Oltman CG, Gbur EF, Mohyuddin MT, Nazmin F, Rahman MS, Jashim A, Crews BC, Kingsley PJ, Klendworth JE, Marnett LJ, Duvall CL, Cook RS. Polymeric Nanoparticles Enable Targeted Visualization of Drug Delivery in Breast Cancer. Mol Pharm [print-electronic]. 2025 Apr 4/21/2025; PMID: 40257460, DOI: 10.1021/acs.molpharmaceut.4c00695, ISSN: 1543-8392.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/30/2024; 9(30): 32853-63. PMID: 39100361, PMCID: PMC11292652, DOI: 10.1021/acsomega.4c03640, ISSN: 2470-1343.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. ACS Omega. 2024 Jul 7/8/2024; DOI: 10.1021/acsomega.4c03640.
Uddin MJ, et al. Polymeric Micellar Nanoparticles Enable Image-guided Drug Delivery in Solid Tumors. BioRxiv. 2024 Jun 6/7/2024; DOI: 10.1101/2024.06.07.598019.
Asaduzzaman A, Thompson CC, Uddin MJ. Machine Learning Approaches for Skin Neoplasm Diagnosis. BioRxiv. 2024 May 5/12/2024; DOI: 10.1101/2024.05.12.593773.
Uddin MJ, Niitsu H, Coffey RJ, Marnett LJ. Development of Pluoronic nanoparticles of fluorocoxib A for endoscopic fluorescence imaging of colonic adenomas [letter]. J Biomed Opt [print-electronic]. 2023 Apr; 28(4): 40501. PMID: 37091910, PMCID: PMC10118138, PII: 220308LR, DOI: 10.1117/1.JBO.28.4.040501, ISSN: 1560-2281.
Aleem AM, Kang W, Lin S, Milad M, Kingsley PJ, Crews BC, Uddin MJ, Rouzer CA, Marnett LJ. Ferroptosis Inhibitors Suppress Prostaglandin Synthesis in Lipopolysaccharide-Stimulated Macrophages. ACS Chem Biol [print-electronic]. 2023 Jan 1/13/2023; PMID: 36638351, DOI: 10.1021/acschembio.2c00869, ISSN: 1554-8937.
Uddin MJ, Lo JH, Oltman CG, Crews BC, Huda T, Liu J, Kingsley PJ, Lin S, Milad M, Aleem AM, Asaduzzaman A, McIntyre JO, Duvall CL, Marnett LJ. Discovery of a Redox-Activatable Chemical Probe for Detection of Cyclooxygenase-2 in Cells and Animals. ACS Chem Biol [print-electronic]. 2022 Jul 7/15/2022; 17(7): 1714-22. PMID: 35786843, DOI: 10.1021/acschembio.1c00961, ISSN: 1554-8937.
Winters ND, Bedse G, Astafyev AA, Patrick TA, Altemus M, Morgan AJ, Mukerjee S, Johnson KD, Mahajan VR, Uddin MJ, Kingsley PJ, Centanni SW, Siciliano CA, Samuels DC, Marnett LJ, Winder DG, Patel S. Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. J Clin Invest [print-electronic]. 2021 Jul 7/22/2021; 131(17): PMID: 34292886, PMCID: PMC8409586, PII: e146861, DOI: 10.1172/JCI146861, ISSN: 1558-8238.
Malerba P, Crews BC, Ghebreselasie K, Daniel CK, Jashim E, Aleem AM, Salam RA, Marnett LJ, Uddin MJ. Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1837-42. PMID: 33062161, PMCID: PMC7549111, DOI: 10.1021/acsmedchemlett.9b00280, ISSN: 1948-5875.
Uddin MJ, Xu S, Crews BC, Aleem AM, Ghebreselasie K, Banerjee S, Marnett LJ. Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1881-5. PMID: 33062168, PMCID: PMC7549255, DOI: 10.1021/acsmedchemlett.9b00555, ISSN: 1948-5875.
Uddin MJ, Vemulapalli A, Niitsu H, Crews BC, Oltman CG, Kingsley PJ, Kavanaugh TE, Bedingfield SK, Mcintyre JO, Milad M, Aleem AM, Coffey RJ, Duvall CL, Marnett LJ. Molecular Imaging of Inflammation in Osteoarthritis Using a Water-Soluble Fluorocoxib. ACS Med Chem Lett. 2020 Oct 10/8/2020; 11(10): 1875-80. PMID: 33062167, PMCID: PMC7549260, DOI: 10.1021/acsmedchemlett.9b00512, ISSN: 1948-5875.
Cekanova M, Pandey S, Olin S, Ryan P, Stokes JE, Hecht S, Martin-Jimenez T, Uddin MJ, Marnett LJ. Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer. J Biomed Opt. 2020 Aug; 25(8): PMID: 32860356, PMCID: PMC7456637, PII: JBO-200044R, DOI: 10.1117/1.JBO.25.8.086005, ISSN: 1560-2281.
Bourn J, Rathore K, Donnell R, White W, Uddin MJ, Marnett L, Cekanova M. Detection of carcinogen-induced bladder cancer by fluorocoxib A. BMC Cancer. 2019 Nov 11/27/2019; 19(1): 1152. PMID: 31775672, PMCID: PMC6882158, PII: 10.1186/s12885-019-6366-x, DOI: 10.1186/s12885-019-6366-x, ISSN: 1471-2407.
Uddin MJ, Wilson AJ, Crews BC, Malerba P, Uddin MI, Kingsley PJ, Ghebreselasie K, Daniel CK, Nickels ML, Tantawy MN, Jashim E, Manning HC, Khabele D, Marnett LJ. Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer. ACS Omega [print-electronic]. 2019 May 5/31/2019; 4(5): 9251-61. PMID: 31172046, PMCID: PMC6545551, DOI: 10.1021/acsomega.9b01093, ISSN: 2470-1343.
Xu S, Uddin MJ, Banerjee S, Duggan K, Musee J, Kiefer JR, Ghebreselasie K, Rouzer CA, Marnett LJ. Conjugated Indomethacin Fluorescent Inhibitors Utilize the Membrane Binding Domain of Cyclooxygenase-2 to Accommodate the Tethered Moiety. J. Biol. Chem. 2019 Apr 4/30/2019; 294(22): 8690-8. PMID: 31000626.
Bourn J, Pandey S, Uddin MJ, Marnett LJ, Cekanova M. Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. Oncotarget. 2019 Jan 1/29/2019; 10(48).
Shaheen SM, Azad AK, Rahman MM, Uddin MJ. A comparative transgene expression study between a protaplex and a rotaplex embedded lipid-nanoparticles in murine derived dendritic cell. J Interdiscipl Nanomed. 2018 Jul 7/10/2018; 0(0).
Cavener VS, Gaulden A, Pennipede D, Jagasia P, Uddin J, Marnett LJ, Patel S. Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Front Neurosci. 2018; 12: 479. PMID: 30108473, PMCID: PMC6080414, DOI: 10.3389/fnins.2018.00479, ISSN: 1662-4548.
Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, Uddin MJ, Plath N, Marnett LJ, Patel S. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biol. Psychiatry [print-electronic]. 2017 Oct 10/1/2017; 82(7): 488-99. PMID: 28438413, PMCID: PMC5585044, PII: S0006-3223(17)31357-4, DOI: 10.1016/j.biopsych.2017.03.002, ISSN: 1873-2402.
Bluett RJ, Báldi R, Haymer A, Gaulden AD, Hartley ND, Parrish WP, Baechle J, Marcus DJ, Mardam-Bey R, Shonesy BC, Uddin MJ, Marnett LJ, Mackie K, Colbran RJ, Winder DG, Patel S. Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nat Commun. 2017 Mar 3/28/2017; 8: 14782. PMID: 28348378, PMCID: PMC5379055, PII: ncomms14782, DOI: 10.1038/ncomms14782, ISSN: 2041-1723.
Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release. Neuron [print-electronic]. 2016 Sep 9/21/2016; 91(6): 1244-52. PMID: 27618677, PII: S0896-6273(16)30509-8, DOI: 10.1016/j.neuron.2016.08.017, ISSN: 1097-4199.
Uddin MJ, Crews BC, Xu S, Ghebreselasie K, Daniel CK, Kingsley PJ, Banerjee S, Marnett LJ. Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. ACS Chem. Biol [print-electronic]. 2016 Sep 9/19/2016; PMID: 27588346, DOI: 10.1021/acschembio.6b00560, ISSN: 1554-8937.
Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A. Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization. J Biomed Opt. 2016 Sep 9/1/2016; 21(9): 90503. PMID: 27626899, PII: 2553360, DOI: 10.1117/1.JBO.21.9.090503, ISSN: 1560-2281.
Adeniji A, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J. Med. Chem [print-electronic]. 2016 Aug 8/25/2016; 59(16): 7431-44. PMID: 27486833, DOI: 10.1021/acs.jmedchem.6b00160, ISSN: 1520-4804.
Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials [print-electronic]. 2016 Jun; 92: 71-80. PMID: 27043768, PMCID: PMC4833621, PII: S0142-9612(16)30049-7, DOI: 10.1016/j.biomaterials.2016.03.028, ISSN: 1878-5905.
Uddin MI, Evans SM, Craft JR, Capozzi ME, McCollum GW, Yang R, Marnett LJ, Uddin MJ, Jayagopal A, Penn JS. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Sci Rep. 2016; 6: 31011. PMID: 27491345, PMCID: PMC4974503, PII: srep31011, DOI: 10.1038/srep31011, ISSN: 2045-2322.
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A. Applications of azo-based probes for imaging retinal hypoxia. ACS Med Chem Lett. 2015 Apr 4/9/2015; 6(4): 445-9. PMID: 25893047, PMCID: PMC4394343, DOI: 10.1021/ml5005206, ISSN: 1948-5875.
Ra H, González-González E, Uddin MJ, King BL, Lee A, Ali-Khan I, Marnett LJ, Tang JY, Contag CH. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A. Neoplasia. 2015 Feb; 17(2): 201-7. PMID: 25748239, PMCID: PMC4351298, PII: S1476-5586(14)00199-7, DOI: 10.1016/j.neo.2014.12.009, ISSN: 1476-5586.
Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ. Design of Fluorine-Containing 3,4-Diarylfuran-2(5H)-ones as Selective COX-1 Inhibitors. ACS Med Chem Lett. 2014 Nov 11/13/2014; 5(11): 1254-8. PMID: 25408841, PMCID: PMC4233350, DOI: 10.1021/ml500344j, ISSN: 1948-5875.
Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹8F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: preliminary investigation. Eur J Med Chem [print-electronic]. 2014 Jun 6/10/2014; 80: 562-8. PMID: 24832612, PMCID: PMC4401082, PII: S0223-5234(14)00403-6, DOI: 10.1016/j.ejmech.2014.04.074, ISSN: 1768-3254.
Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ. Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Med Chem Lett. 2014 Apr 4/10/2014; 5(4): 446-50. PMID: 24900856, PMCID: PMC4027729, DOI: 10.1021/ml400485g, ISSN: 1948-5875.
Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ. The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor. ACS Med Chem Lett [print-electronic]. 2013 May 5/9/2013; 4(5): 486-90. PMID: 23687559, PMCID: PMC3654564, DOI: 10.1021/ml400066a, ISSN: 1948-5875.
Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ. Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents. Bioconjug. Chem [print-electronic]. 2013 Apr 4/17/2013; 24(4): 712-23. PMID: 23488616, PMCID: PMC3630741, DOI: 10.1021/bc300693w, ISSN: 1520-4812.
Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev Res (Phila) [print-electronic]. 2011 Oct; 4(10): 1536-45. PMID: 21900596, PMCID: PMC3214660, PII: 1940-6207.CAPR-11-0120, DOI: 10.1158/1940-6207.CAPR-11-0120, ISSN: 1940-6215.
Uddin MJ, Schulte MI, Maddukuri L, Harp J, Marnett LJ. Semisynthesis of 6-chloropurine-2'-deoxyriboside 5'-dimethoxytrityl 3'-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its use in the synthesis of fluorescently labeled oligonucleotides. Nucleosides Nucleotides Nucleic Acids. 2010 Nov; 29(11): 831-40. PMID: 21128170, PMCID: PMC3019237, PII: 930388354, DOI: 10.1080/15257770.2010.530332, ISSN: 1532-2335.
Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010 May 5/1/2010; 70(9): 3618-27. PMID: 20430759, PMCID: PMC2864539, PII: 70/9/3618, DOI: 10.1158/0008-5472.CAN-09-2664, ISSN: 1538-7445.
Uddin MJ, Smithson DC, Brown KM, Crews BC, Connelly M, Zhu F, Marnett LJ, Guy RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg. Med. Chem. Lett [print-electronic]. 2010 Mar 3/1/2010; 20(5): 1787-91. PMID: 20129783, PMCID: PMC2826502, PII: S0960-894X(10)00011-9, DOI: 10.1016/j.bmcl.2010.01.009, ISSN: 1464-3405.
Konkle ME, Hargrove TY, Kleshchenko YY, von Kries JP, Ridenour W, Uddin MJ, Caprioli RM, Marnett LJ, Nes WD, Villalta F, Waterman MR, Lepesheva GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J. Med. Chem. 2009 May 5/14/2009; 52(9): 2846-53. PMID: 19354253, PMCID: PMC2744100, DOI: 10.1021/jm801643b, ISSN: 1520-4804.
Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J.. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals. 2009; 52: 387-93.
Uddin MJ, Marnett LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org. Lett [print-electronic]. 2008 Nov 11/6/2008; 10(21): 4799-801. PMID: 18837556, PMCID: PMC2646678, DOI: 10.1021/ol801904k, ISSN: 1523-7052.
Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B.. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood. 2006; 13: 4059.
Uddin MJ, Rao PN, McDonald R, Knaus EE. Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg. Med. Chem. Lett. 2005 Jan 1/17/2005; 15(2): 439-42. PMID: 15603969, PII: S0960-894X(04)01291-0, DOI: 10.1016/j.bmcl.2004.10.050, ISSN: 0960-894X.
Uddin MJ, Praveen Rao PN, Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity. Bioorg. Med. Chem. 2005 Jan 1/17/2005; 13(2): 417-24. PMID: 15598562, PII: S0968-0896(04)00791-6, DOI: 10.1016/j.bmc.2004.10.017, ISSN: 0968-0896.
Uddin MJ, Praveen Rao PN, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Nov 11/18/2004; 47(24): 6108-11. PMID: 15537365, DOI: 10.1021/jm049523y, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. 2004 Nov 11/15/2004; 12(22): 5929-40. PMID: 15498669, PII: S0968-0896(04)00624-8, DOI: 10.1016/j.bmc.2004.08.021, ISSN: 0968-0896.
Uddin MJ, Rao PN, Rahim MA, McDonald R, Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Oct 10/4/2004; 14(19): 4911-4. PMID: 15341950, PII: S0960-894X(04)00919-9, DOI: 10.1016/j.bmcl.2004.07.027, ISSN: 0960-894X.
Rao PN, Uddin MJ, Knaus EE. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2004 Jul 7/29/2004; 47(16): 3972-90. PMID: 15267236, DOI: 10.1021/jm049939b, ISSN: 0022-2623.
Uddin MJ, Rao PN, Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2004 Apr 4/19/2004; 14(8): 1953-6. PMID: 15050635, PII: S0960894X04001556, DOI: 10.1016/j.bmcl.2004.01.075, ISSN: 0960-894X.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.. Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett. 2004; 1513.
Uddin MJ, Rao PN, Knaus EE. Design and synthesis of novel celecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the sulfonamide pharmacophore by a sulfonylazide bioisostere. Bioorg. Med. Chem. 2003 Nov 11/17/2003; 11(23): 5273-80. PMID: 14604691, PII: S0968089603005583, ISSN: 0968-0896.
Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry. 2003; 40: 861.
Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I.. Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure ?-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity. Synthesis. 2000; 365.
Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I.. Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications. 2000; 6: 113.
Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I.. Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications. 2000; 6: 505.